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Abstract  
 
Cystic Fibrosis  (CF) is the commonest life limiting inherited disease illness in the 
western world. Over the last few decades there have been many advances in the 
diagnosis and management of this condition. Patients born with the disease now are 
living into their fourth decade, which is a statement to the progress made over time. 
 
Along with the progress there have been new challenges in the world of CF. In the last 
two decades there have been several studies reporting the presence of transmissible 
Pseudomonas Aeruginosa (Psa) strains in CF clinics worldwide. The first one to be 
reported in UK Liverpool paediatric clinic was later identified as the Liverpool 
Epidemic Strain (LES). Previous studies have demonstrated chronic infection with LES 
can result in accelerated fall in lung function, increased hospitalisation and antibiotic 
requirements. This thesis looks at the effect of chronic infection of adults with CF and 
its implications on healthcare institutions caring for such patients. In particular on an 
individual level i investigated the health related quality of life associated with patients 
chronically infected with LES and compared it those with unique or no Psa strains. I 
have demonstrated that chronic infection with LES strain significantly worsens health 
related quality of life compared to those with unique or no Psa strains. Patients infected 
by transmissible Psa strains had worse physical functioning, respiratory symptoms, 
treatment burden, vitality, role, health perception and emotion than those with unique 
Psa strains (p<0.01), and significantly poorer physical functioning, respiratory 
symptoms, treatment burden, body image, weight, role, and emotion than those without 
any Psa infection (p<0.05). 
 
 13 
To understand the susceptibility of LES strains to common anti-pseudomonal antibiotics 
I studied the antibiograms of patients infected with LES strain over a 5-year period and 
compared the change in susceptibility to those infected with unique Psa strain. LES 
exhibited significantly more resistant isolates in 2004 (p<0.0001). There was an 
increase in antibiotic resistance in both LES and other Psa strains over time (p<0.001). 
Cox proportional hazards analysis of both unmatched (n=125) and matched (n=56) 
patients in 2004 revealed that LES infected patients were more likely to develop 
antibiotic resistant isolates over time (hazard ratio 8.1, p<0.001). Fewer LES isolates 
were classed as fully sensitive in both matched and unmatched groups at the end of 
study period (p<0.001). 
 
 I then looked at the phenotypic characteristics exhibited by LES strain in comparison 
with unique Psa strain during an infective episode to elucidate whether it is a specific 
character of LES assisting to survive in harsh CF environment. We analyzed sets of 40 
sputum samples isolates from five CF patients each chronically infected with a different 
non-LES strain of P. aeruginosa.  For each sample (two per patient), diversity was 
assessed by characterising nine phenotypic traits.  All P. aeruginosa populations were 
highly diverse. The majority of phenotypic variation found was due to within-sample 
variation. I demonstrated that maintenance of diverse populations in the CF lung is a 
general feature of P. aeruginosa infections rather than a unique characteristic of LES. 
To assess the healthcare resource implication on institutions caring for such patients we 
carried out an economic analyses of healthcare utilisation of patients chronically 
infected with LES to those with unique Psa strain over a four-year period. Ascertainable 
costs were correlated in these two groups of patients. The mean cost per patient per year 
was higher for LES patients for inpatient care (£4393.37 v £1817, p=0.0006), outpatient 
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attendance (£3764 v £2515.91, p=0.0035) and also hospital antibiotic therapy (£980 v £ 
505, p=0.001). Regular prescription costs were similar in both groups. Overall, the 
healthcare cost of caring for an adult CF patient with LES chronic infection was 
significantly more (1.6 times) than that for a matched patient with unique Psa strain 
chronic infection. 
Finally, I looked the effects of segregation policies instituted at Liverpool adult Cf 
centre in limiting cross infection. Regular genotypic surveillance of sputum samples of 
all patients was instituted to monitor cross infection rates. This study elucidated the 
cross infection policies over a 7-year period and looked at the yearly number of patients 
with LES and other strains. There was a decline in the proportion of patients with LES 
(71% to 53%) and an increase in those with unique strains (23% to 31%) and without 
Psa infection (6% to 17%) over the study period.  
Areas of potential future research based on this thesis are also outlined. 
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1.1 Epidemiology: 
Cystic fibrosis (CF) is the most common life shortening, autosomal recessive 
disorder in the Caucasian population. In the UK the incidence is about 1 in 2500 live 
births and about 1 in 25 are carriers. Following major advances in understanding of 
the disease, genetics, microbiology and multidisciplinary approach to management, 
the average lifespan of a patient with CF has increased. The median predicted 
survival now is between 37-47 years (UK CF registry 2013, Canadian CF registry 
2009). This is indeed a dramatic leap from four decades ago, when only 10% of CF 
patients were over the age of 18 years (Yankaskas et al 2004) and the focus of the 
disease management was on managing end-stage disease. As the survival of patients 
born with CF has increased over the years, the number of adults with CF is expected 
to surpass the number of cases in paediatric settings, which indicates the changing 
landscape of the average age of a CF patient. In the UK there is an increasing 
proportion (>70%) of CF diagnosis made within the first three months of life, with 
90% occurring within the first year (UK CF registry 2013). It is now not uncommon 
for CF patients to enjoy facets of life which were previously limited to “normal” 
individuals, such as completing education, holding jobs and having a family. The 
recent UK CF registry (2013) suggests that in the UK 71% of all adults with CF are 
in full time jobs or education, and that this is improving year on year. However there 
are still problems that need to be overcome to achieve a normal lifespan and quality 
of life for these individuals. Chronic infections with Pseudomonas aeruginosa (Psa), 
which adversely affects patients with CF, is still a problem experienced by all CF 
centres in the world. Despite all these advances the median age at death still remains 
at a sobering 29 years (UK CF registry 2013), which still suggests that there is still a 
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long way to go and efforts at improving outcomes for these patients need to be 
continued tirelessly. 
1.2 CF genetics 
CF is an autosomal recessive condition caused by mutations in a single gene, 
located on the long arm of chromosome 7, which encodes a 1480 residue 
transmembrane glycoprotein called the CF transmembrane conductance regulator 
(CFTR) ( Davies et al 1996, Welsh MJ & Smith 1993). It is the most common life-
limiting genetic disease seen in the western world. There are about 1500 reported 
mutations, many of which are rare and may not result in clinical signs or symptoms.  
The majority of mutations involve less than three nucleotides leading to 
predominantly amino acid substitutions, frame shift or nonsense mutations (Gibson 
et al 2003). Of these 1500 mutations, only 22 have been identified with frequency of 
at least 0.1% known alleles (CF Consortium 1990) and have been demonstrated by 
direct evidence to cause sufficient loss of CFTR function to cause CF clinically and 
would be accepted for a genetic basis of diagnosis. Most of the other mutations are 
rare, restricted to a limited population and don’t usually result in clinical disease.  
The first identified mutation and the most common has a three base pair deletion 
that codes for phenylalanine at position 508 of the CFTR protein. This p.Phe508del 
mutation is the most common in the Caucasian population, accounting for over 90% 
of CF-related alleles (UK CF Registry 2013). The various mutations affect the 
function of CFTR in different ways; some resulting in abnormal CFTR production 
and others affect the intracellular processing of CFTR channel function or a 
combination of these (Zielenski & Tsui 1995) (Table 1). These specific mutations 
can have characteristics of more than one class. These mechanisms of CFTR 
dysfunctions are a simplistic framework in understanding the molecular basis of 
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epithelial abnormalities in CF. Most of the diagnosis however requires a 
combination of clinical disease associated with CF sweat chloride testing or nasal 
potential difference in combination of gene testing (Farrell et al 2008). There are 
newborn screening tests, which are available in the western world to aid early 
diagnosis. Patients without clinical spectrum of the disease but positive diagnostic 
tests or vice versa are usually followed up as they are at a higher risk of 
complications associated with CF. 
Table 1 Classes of CFTR mutations 
Class of 
mutation 
CFTR production and function 
Class 1 
mutation 
Defective protein production with premature termination of CFTR 
Protein production. No functioning CFTR chloride channels seen 
Class 2 
mutation 
Defective trafficking of CFTR so that it does not reach the apical 
surface membrane where it is intended to function 
Class 3 
mutation 
Defective regulation  (opening and closing) of the CFTR chloride 
channel  
Class 4 
mutation 
Defective conduction (passage of chloride ions through the channels) 
Class 5 
mutation 
Reduced synthesis of functional CFTR 
 
1.3 Function of CFTR 
CFTR acts as a Cyclic adenosine monophosphate regulated chloride channel at the 
apical membrane of various epithelial cells at sites including the sweat glands, salivary 
glands, airways, nasal epithelium, vas deferens in males, bile ducts, pancreas, intestinal 
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epithelium as well as many other sites (Welsh, MJ 1995). The function of CFTR is 
important in many of these organs as its defectiveness, mislocalisation or absence 
causes disease (Davies et al 1996). CFTR mediates transepithelial salt transport, liquid 
movement and ion concentrations in these organs (Tummler et al 1997). The structure 
of CFTR places it in the family of transport proteins called ATP binding cassette (ABC) 
transporters. (Cheng et al 1990)  Members of this family utilise the energy of ATP 
hydrolysis to transport substrates across cell membranes.  
CF reflects the absence of a functional CFTR protein at a cellular level (Welsh et al 
1993). The various CFTR mutations are outlined in Table 1). The most common CF 
mutation, F508, has been demonstrated to exhibit a problem in polypeptide maturation 
and translocation to the appropriate cellular domain, e.g. the apical membrane (Cheng et 
al 1990).  
CFTR also regulates the movement of other ions across these trans-membranous 
channels; i.e stimulation of other chloride channels or inhibiting the epithelial sodium 
channel resulting in salt and water transport across epithelial barriers. CF is 
characterised by a wide variety of clinical expression relating to CFTR defects: 
dehydration and hyperviscosity of mucous secretions result in plugging of the ducts of 
exocrine glands which then predispose to multi-organ clinical manifestations, 
particularly within gastrointestinal, hepato-biliary, reproductive and respiratory tracts 
(Boucher R et al 2004). The main clinical features may include chronic suppurative 
lung disease, exocrine pancreas insufficiency, intestinal obstruction, gallstones, biliary 
cirrhosis and male infertility. However the most important site of disease that accounts 
for much of the morbidity and mortality is the lung. 
1.4 Abnormal innate lung defense in CF  
Recent studies have demonstrated that bronchiectasis can be seen in 22% of newborn 
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with CF (Stick et al 2009). BAL studies in these infants, as early as 3 months, has 
shown infection with microorganisms (Mott et al 2011).  Early infections in CF occur 
with more benign bacteria such as Haemophilus influenza and Staphylococcus aureus. 
By adulthood 80% are infected with Pseudomonas aeruginosa (Kerem et al1990). At a 
very basic level, CF lung disease could be seen as a failure of the innate defense 
mechanisms of the lung against inhaled microorganisms (Knowles et al 2002). Absence 
of functional CFTR, which causes problems with ion transport, leads to further 
problems in the defense mechanisms of the lung, which may result in persistence of 
bacterial pathogens in the lung leading to a chronic cycle of inflammatory response and 
lung damage. 
 Two popular theories have been developed to link the ion transport defects to the innate 
defense of airways against inhaled bacterial pathogens: firstly the failure of mechanical 
clearance of the bacteria and secondly the ion transport abnormalities causing alteration 
of the depth and tonicity of the periciliary fluid. Normally, once a bacterial pathogen is 
inhaled, mechanical clearance has been viewed as the primary innate defense 
mechanism. Mucus clearance provides the mechanical clearance that removes bacteria 
from the airways within few hours under normal conditions (Wanner et al 1996). 
Airway surface liquid (ASL) is composed of mucus and an underlying watery 
periciliary liquid (PCL). The promotion of efficient mucus transport requires 
coordination of events such as the efficient ciliary activity and the regulation of 
adequate quantity of ions and water on airway surfaces via the trans-epithelial transport 
channels. The capacity of the epithelium to maintain the PCL layer at the appropriate 
height requires the adjustment of ASL volume, a process that is believed to be mediated 
by isotonic volume transport (Matsui et al 1998, Tarran et al 2001). The 
microorganisms are usually trapped in the mucus layer.  The cilia move from the small 
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distal to the larger proximal airway carrying along with it the mucus, periciliary surface 
liquid and the microorganism eventually leading to its clearance from the lung. The 
second hypothesis of airway defense was formed in 1990s for airways defense that 
focused on the role of antimicrobial peptides in ASL to provide a chemical shield on the 
airway surface as the primary defense (Goldman et al 1997, Smith JJ et al 1996). For 
this shield to be effective, two processes must be normally regulated by the airway 
epithelium. First, there must be secretion of the appropriate quantities of antimicrobial, 
salt-sensitive peptides (defensins), and secondly, the ASL must be modified, i.e. made 
hypotonic (w50 mM NaCl), so that antimicrobials are active. It has also been 
demonstrated that in the airway antimicrobial substances such as lactoferrin and 
lysozyme are present, which suppress bacterial growth over time. (Cole et al1999) 
The mucus layer serves to trap inhaled material during the clearance process from the 
airways. The mucus layer uses two mechanisms to remove virtually all inhaled particles 
that deposit on airway surfaces: 1) mucus flow is "turbulent", so materials are mixed 
into the mucus layer and enmeshed/ trapped during clearance (Worlitzsch et al  2002) 
mucin molecules exhibit a layer of carbohydrate epitopes to ensure low affinity binding 
to most particles ( Lamblin et al 2001). 
To maintain a steady state in PCL needs a balance of Na
+
 absorption and Cl
-
 secretion. 
The epithelial cells express the epithelial Na
+
 channels (ENaC) and pumps Na
+
/K/- 
ATPase to mediate intracellular Na
+
 absorption. When ENaC is inhibited there are 
electrical driving forces that initiate the Cl
-
 secretion. This chloride secretion is 
mediated by CFTR. Lately the importance of both the accelerated Na
+
 absorption and 
the failure to initiate Cl
-
 secretion to the abnormal ASL volume homeostasis in CF has 
become clear.  These abnormalities in both processes ultimately lead to depletion of the 
PCL layer and formation of thickened mucus plugs adherent to CF airways. This 
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reduction in ASL has been demonstrated to cause the spontaneous airway inflammation 
A reduction in ciliary-dependent clearance results from thickening of the mucus 
rendering it less favorable for transport. Regnis (1994) have demonstrated reduced 
mucociliary clearance in CF patients with normal lung function compared with age-
matched normal subjects. 
1.5 Mucus hypoxia and bacterial colonization 
Mucin secretion from goblet cells and submucosal glands continues despite this highly 
dysregulated mucus transport in patients with CF. This continued secretion of mucins 
into an already thickened mucus layer eventually lead to formation of mucus plaques 
and plugs on airway surfaces. As these plaques can reach heights of 1 cm in adult 
patients, the areas of these plaques near the CF cell surface become oxygen depleted 
(Worlitzsch et al 2002). In normal circumstances the turbulence of a normally 
functioning mucus layer will trap the microorganism leading to its clearance. However, 
as the mucus transport is impaired, some bacteria such as P. aeruginosa can easily 
penetrate into this thickened mucus plaque and migrate into hypoxic zones. P. 
aeruginosa adapts to this hypoxic environment by slowing its growth and by production 
of alginate. This formation of alginate reflects the conversion from the planktonic 
growth seen in the environment to one that is suited more to the anaerobic CF 
environment (i.e biofilm mode). 
With these successful adaptations to the hostile CF environment by P. aeruginosa the 
scene is set for persistent infection. This mode of anaerobic growth provides a lot of 
advantages to the microorganism. Primarily the neutrophil mediated damage is limited 
in such an environment as it may be difficult for migratory neutrophils to penetrate into 
the thickened mucus plaques. Also, the diffusion of antimicrobial activities into the 
thickened mucus plaques may be limited. This failure of the secondary defence 
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mechanisms to fight P. aeruginosa, and the persistence of bacteria in the “protective 
environment” of biofilm, leads to a persistent state of infection of the adherent mucus 
(Worlitzsch et al 2002). This proliferant bacterial growth over time renders the mucus 
layer totally oxygen deficient. This anaerobic state of mucus layer and persistent 
bacterial colonization has implications in CF treatment. The minimal inhibitory capacity 
of the antimicrobial agents in an anaerobic biofilm environment may not be well 
represented by the laboratory condition usually employed during routine testing (De 
Kievit et al 2001).  
1.6 Clinical Manifestations of Mutations in CFTR Defects  
Most of the clinical manifestations seen in CF are due to the pathophysiological effects 
of the thickened mucus produced by the epithelial layer of apical acinar cells (Sheppard 
et al 2002). The destruction of the exocrine pancreas is attributed to tissue damage due 
to lytic enzymes of the acinar tissue following plugging of the pancreatic ducts by the 
thickened secretions of the pancreatic acinar cells leading to fibrosis and fatty 
replacement. Older patients have an increasing incidence of diabetes mellitus, 
associated with destruction of the pancreas (Costellessa et al 2000). The gastro-
intestinal manifestation of malabsorption of essential fats is due to reduced intestinal 
fluid secretion combined with inadequate pancreatic secretion. This leads to failure to 
thrive in newborns and gastro-intestinal blockage known as meconium ileus, seen in 
approximately 5 to 10% of patients (Murshed et al 1997). Rectal prolapse can also be 
seen in up to 20% of untreated patients with CF in the first 5 years of life (Kulczycki et 
al 1958). Older patients can present with a clinical picture very similar to bowel 
obstruction, wherein distal intestinal obstruction syndrome can develop if fluid intake is 
poor or there is a failure to take pancreatic enzymes. Similarly, obstruction of the 
hepatic ducts has been hypothesized to be the etiology of the liver disease in CF. Bile 
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stasis and periportal fibrosis can often result in cirrhosis of the liver and ensuing 
complications such as portal hypertension and varices can also be seen (Roy et al 1982). 
Patients can also present with pan-sinusitis due to the mucociliary apparatus failure and 
electrolyte abnormalities, especially in summer months due to loss of electrolytes in 
sweat. Females are sub-fertile due to altered cervical viscosity. In males however there 
is congenital bilateral absence of the vas deferens (CBAVD), which renders most males 
infertile (Anguiano et al 1992). A primary defect in calcium metabolism and increase in 
urinary oxalate excretion has been linked to patients developing kidney stones 
(Matthews et al 1996).  Many patients with CF suffer with malnutrition because of 
defects in their pancreatic and gastro-intestinal function. They have poor weight gain, 
muscle mass and short stature. Osteoporosis, low bone mass and fractures are common 
in both children and adults with CF (Sheppard et al 2002). Most cardiovascular 
manifestations are due to right heart failure and pulmonary hypertension (Stern et al 
1980). Myocardial necrosis and fibrosis can lead to sudden cardiac arrest in childhood 
(Żebrak et al 2000). Neuro-pathological changes in CF resemble those of vitamin E 
deficiency, including dystrophic axons and demyelination. In animal models 
replacement of vitamin E has been shown to halt these changes (Sung et al 1980). 
1.7 Airways in Cystic Fibrosis 
The main clinical feature of CF lung disease is chronic airway infection and repeated 
infective exacerbations leading to irreversible lung damage and death (Kerem et al 
1990). Although the CF lung is normal in utero and during first few months of life 
(Sturgess et al 1982), many infants become infected with bacteria and develop airway 
inflammation. Mucosal plugging of small airway may be the earliest indication of lung 
disease. Infants with CF get infected by microorganisms within the first few months of 
life. There is evidence, as discussed below, to suggest that such chronic colonisation of 
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microorganisms is preceded by vigorous inflammatory response by the immune system. 
Early infections are deemed more due to pathogens such as S aureus and H. influenzae, 
but by adulthood 80% of CF patients are chronically colonised with P. aeruginosa, 
which ultimately causes the morbidity associated with CF. The inflammatory responses 
within the lungs to these microorganisms, the chronology of chronic colonisation, and 
the adaptations by microorganisms to enable survival in CF lungs will now be 
discussed.  
1.8 Exaggerated inflammatory response in airways 
CF infants develop bacterial infections early and the airway epithelial cells respond by 
mounting a vigorous inflammatory response (Stick et al 2009).  CF disease involves a 
whole host of inflammatory mediators including cytokines such as IL-6, IL-8, 
granulocyte macrophage stimulating factor (GM-CSF) and Tumour necrosis factor 
(TNF)-. A large influx of neutrophils occurs into the lungs. Some of these mediators, 
such as TNF- and interleukins (IL)-1, stimulate the epithelial cells to produce further 
pro-inflammatory cytokines using different signalling pathway than accessed by 
bacterial products, which leads to a overwhelming influx of these mediators in the 
lungs. In a study of children under the age of 12 with CF, all the children had evidence 
of pathogens in the lungs (Konstan et al 1994). The BAL of CF lungs predominantly 
were found to be infiltrated with neutrophils (57%, compared to 3% of controls). The 
mean concentration of neutrophils was found to be 380 times of that of controls, which 
is indicative of the exuberant inflammatory response seen in CF (Muhlebach et al 
1999). The neutrophils in the lungs may also survive for longer in the CF lungs due to 
the presence of excess GM-CSF and lack of IL-10 (Bonfield et al 1995, Bonfield et 
al1999). The neutrophils and their products such as elastase when present in excess 
further diminish the host’s ability to fight infections, causing active lung damage. This 
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also impairs the function of neutrophil mediated, complement directed, phagocytosis of 
P. aeruginosa, hence impairing the two most important mechanisms of clearing the 
bacteria.  Studies in children have also suggested that they have a positive antibody 
response 12 months prior to first cultures being positive for P. aeruginosa (Heijerman et 
al 2005). A study by Khan et al where BAL samples of 16 infants with CF were 
examined, showed evidence of high levels of IL-8 even when cultures were negative for 
microorganisms, suggestive of exaggerated immune response even in infants with 
relatively normal lungs (Khan et al 2011). Airway macrophages were suggested as the 
source of IL-8, which further leads to neutrophil influx and long term lung damage. 
Bonfield et al. demonstrated excess of macrophages in CF lungs, which causes an 
increase in proinflammatory cytokines such as IL-8, IL-1, tumour necrosis factor (TNF) 
–alpha, IL-6 (Bonfield et al. 1999). There was also a reduction of IL-10, which is the 
cytokine synthesis factor inhibitor leading to an unregulated concentration of 
inflammatory cytokines and to enhanced lung damage. Eventually because of CFTR 
defects the bacteria are retained within the CF lung, causing these inflammatory 
responses to be florid and resulting in long term damage of the lungs. 
1.9 Adaptation by bacteria to survive in CF environment 
In CF, chronic bacterial infections display a limited spectrum. During early years, 
organisms such as H. influenzae and S. aureus dominate, but by adulthood 80 % of the 
CF patients are colonised by P. aeruginosa. (Gilligan et al 1991, Bauernfeind et al 
1987, Gilligan et al 1991, Rosenfield et al 1999). P. aeruginosa is not generally able to 
cause infections in normal hosts, but becomes pathogenic in patients with weakened 
defences. The pathogen can cause a wide range of infections in patients whose natural 
defences are in some way compromised, including burns infections, wound infections, 
eye infections, urinary tract infections, infections in Intensive Care Units or Neonatal 
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Units, as well as infection associated with lung disease, most notably CF (Pitt,T.L 1986,  
Lyczak et al 2002). The CF lung is a very hostile and heterogeneous environment in 
which the colonising microorganisms have to adapt to survive. Over time P. aeruginosa 
undergoes many genotypic and phenotypic changes to adapt to the CF environment. It 
has been shown that some strains of P. aeruginosa have the ability to mutate rapidly in 
the lungs of patients with CF (Oliver et al 2000). These “hypermutable strains” have 
been demonstrated to show resistance to multiple classes of antibiotics. Yet another 
important mechanism of survival of P. aeruginosa in CF lungs is the production of the 
exopolysaccharide alginate, which leads to a mucoid colony phenotype and is a marker 
for the establishment of chronic infection (Govan & Deretic 1996). In CF lungs a steep 
concentration gradient exists between airway lumen and interior of mucous (Worlitzsch 
et al 2002), which further aids the survival of this organism (Govan et al 1993). This 
adaptation also protects the bacteria from antibiotics and renders the organism 
multiresistant and aids its survival. There are some other well-studied phenotypic 
changes seen in CF isolates of P. aeruginosa to aid survival. These include the loss of 
O-side chains on lipopolysaccaride (LPS) (Hancock et al 1983), flagella- dependent 
motility (Luzar et al 1985), distinctive acylation of LPS (Ernst et al 1999), and 
increased auxotrophy (Thomas et al 2000). The ability of P. aeruginosa to form 
biofilms is also important for their success in the CF lungs (Silby et al 2011, Høiby et al 
2010). P. aeruginosa also undergoes genotypic changes for its survival. It has one of the 
largest bacterial genomes and this offers it the potential to adapt to varied environments. 
1.10 Microbiological aspects of cystic fibrosis lung infection  
In the healthy respiratory system, the upper respiratory tract is usually colonized by a 
host of microorganisms that make up the normal commensal flora while the lower 
respiratory tract is kept in a sterile state by the various defense mechanisms of the host. 
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There are various innate defense mechanisms, which an organism has to overcome prior 
to mounting an infection/inflammatory response. A robust immune system is active at 
all times to keep us protected against infection. These barriers can be classed as physical 
barriers such as skin, epithelium or phagocytic barriers such as the macrophages or 
neutrophils at a more cellular level. Failure of these innate defense systems results in 
susceptibility to infection of our respiratory tract. Patients with CF are prone to such 
infections due to a combination of many factors such as CFTR defect, exaggerated 
immune response, and predilection to and persistence of certain microorganisms in the 
respiratory tract, eventually leading to recurrent infections. Infants with CF are often 
unable to expectorate sputum, which is usually derived from secretions in their lower 
respiratory tract, and therefore oropharyngeal or throat swab cultures, which target the 
upper respiratory tract secretions, are generally performed to detect pathogens. In 
reality, these cultures detect organisms, including potentially pathogenic ones, present 
in the throat and not necessarily in the lungs. There has been some correlation between 
the microbial content of upper and lower respiratory tract secretions, as studied by 
Ramsey et al. In a study of 250 non-expectorating CF infants under the age of 18 
months, the positive predictive value of a positive oropharyngeal culture was 
approximately 95% and negative predictive value was 44%, which is suggestive that 
negative cultures in this cohort were unreliable.  S aureus is commonly the first 
pathogen to infect the lungs of CF patients (Ramsey et al 1991). H. influenzae is also a 
common respiratory coloniser seen in the early years of a CF patient. Since the advent 
of potent antibiotics and the emergence of more pathogenic organisms these organisms 
are now not considered to be so important in the microbiology of CF. S. aurues is often 
found as  a colonizer in the anterior nares of patients, which is a subsequent risk factor 
for future infections (Perl et al 2002, Wenzel et al 1995). Following treatment with 
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intravenous antibiotic the prevalence of S. aureus colonization is reduced (Goerke et al 
2000). It often remains unclear whether isolation of such organism reflects benign 
colonization or pathogenic disease state.  CF patients may be infected with same strain 
of S. aureus for up to 2 years (Branger et al 1996). Lately an increase in prevalence of 
MRSA has been noted in CF clinics, especially in USA (CF registry 2002). It is 
reported that upto 23% of patients in CF clinics in the USA have had MRSA isolated 
from respiratory specimens. MRSA acquisitions have mostly been reported in 
hospitalized patients, suggestive of a potential reservoir of this bacterium. (Bell et al 
2000). Although the implications of MRSA colonization remain unclear, it has been 
reported that children with chronic colonization required increased intravenous 
antibiotics and had a poorer chest radiograph score with no effect on lung function or 
growth (Miall et al 2001).  Therefore some CF clinics advocate using prophylactic 
antibiotic on isolation of S. aureus. However, whilst there is a consensus among 
clinicians about a beneficial effect from treatment of staphylococci associated with 
clearance of the organism from the sputum, there are no data indicating that this 
treatment leads to improved lung function or other clinical benefit (Smyth &Walters, 
Cochrane database review, 2012). 
A 3-year study of over 3000 CF patients in the European Registry of Cystic Fibrosis 
demonstrated that continuous anti-staphylococcal prophylaxis increases the rate of 
patients converting from a non-P. aeruginosa to P. aeruginosa-positive status (Ratjen et 
al 2001). The patients in this study were categorized both according to their age and 
whether they received continuous (200 or more days per year), intermittent (only during 
acute exacerbations), or no anti- staphylococcal therapy. This study demonstrated that 
children under the age of 6 receiving continuous anti-staphylococcal therapy had a 
higher prevalence of P. aeruginosa in their sputum sample than in those receiving no or 
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only intermittent therapy. This difference was not significant over the age of 12. There 
was no significant difference in other prognostic markers of disease severity such as 
BMI & FEV1 between the three antibiotic treatment groups. This observation linked the 
possibility of long term anti-staphylococcal antibiotic prophylaxis resulting in P. 
aeruginosa acquisition (Govan et al 1992, Emminger et al 1987, Geddes et al 1988). 
This has important implication as long-term outcomes for CF patients are much better 
in patients without P. aeruginosa infection (Huang et al 1987, Hudson et al 1993). 
However, further studies are needed to better understand the clinical importance of 
clearing S. aureus and the potential consequences for P. aeruginosa infection (Smythe 
&Walters, Cochrane database review, 2012). 
Burns et al demonstrated that there was evidence of P. aeruginosa in BAL (Broncho-
alveolar lavage) samples in 72% of children under the age of 3 years. When combined 
with serological testing they found evidence of P. aeruginosa in 97.5% of patients with 
P. aeruginosa, which contradicts the hypothesis that staphylococcal infection is a 
precursor for future P. aeruginosa colonization (Burns et al 2001) It is notable that 80% 
of the P. aeruginosa isolates in this study were non -mucoid variant which were 
susceptible to antibiotics rather than the mucoid variant which is the classic variant 
associated with morbidity in CF chronic infections. The P. aeruginosa undergo the 
phenotypic changes to mucoid variant over time as a survival response to adapt to 
hostile CF environment. 
Recent studies have shown that the microbiology of the CF lung is far more 
complicated than was originally thought, with many bacterial species, including 
anaerobes, co-existing as part of a complex CF “microbiome” (Blainey et al  2012). The 
clinical relevance of this is not yet understood. 
1.11 P. aeruginosa in CF 
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a) Initiation and establishment of P. aeruginosa infection: 
P. aeruginosa is a ubiquitous organism found in the environment. It is a commensal of 
the upper respiratory tract in 5-10% of the normal population and asymptomatically 
exists in the GI tract of CF patients in up to 20% of cases (Speert et al 1993). This 
presence of P. aeruginosa in the environment means that CF patients are constantly 
exposed to this opportunistic pathogen.  Although CF patients can acquire P. 
aeruginosa in their respiratory tracts at any time, studies have shown that 70 to 80% of 
CF patients are chronically infected with P. aeruginosa by their teen years. Once P. 
aeruginosa chronically colonizes the lung, it results in long-term lung infections 
generally requiring intravenous antibiotics. The diversity of P. aeruginosa strains 
isolated from CF patients suggests that most clinical isolates are acquired from the 
surrounding environment (Burns et al 2001, Sogbanmu et al 1980). 
b) Progression of chronic infection 
Although there is a highly varied clinical course for CF patients based on acquisition of 
various well-known prognostic factors, the establishment of chronic infection with P. 
aeruginosa is perhaps the most significant. Long-term lung function is best preserved in 
individuals who remain uninfected with P. aeruginosa for as long as possible. Prior to 
the conversion to chronic infection, there is an opportunity to eradicate the P. 
aeruginosa.  Indeed there has been considerable progress in this respect, with the wide 
scale use of Early Eradication Therapy (Smyth &Walters, Cochrane database review, 
2012).Once the mucoid phenotype of P. aeruginosa emerges, this correlates with the 
onset of significant deterioration in lung function (Pedersen et al 1992, Demko et al 
1995).   The mucoid variant is known to be due to the overproduction of an exo-
polysaccaride, alginate, which is a negatively charged, linear copolymer of partially O-
acetylated β-1,4-linked d-mannuronic acid and its C5 epimer, α-l-guluronic acid (Govan 
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& Deretic 1996). This alginate production is a key factor in the pathogenic picture, 
along with several other molecular changes to P. aeruginosa isolates from CF patients. 
Curiously, mucoid P. aeruginosa strains almost all produce a LPS, rendering the 
organisms susceptible to the bactericidal effects of complement (Schiller et al 1984, 
Pier et al 1984). However, effective complement levels in the lungs are below those 
capable of killing mucoid P. aeruginosa strains.  The conversion of P. aeruginosa 
microcolonies from a non-mucoid to a mucoid phenotype marks the transition to a more 
persistent state, characterized by antibiotic resistance and accelerated pulmonary decline 
(Pedersen et al 1992, Govan and Deretic, 1996, Lyczak et al 2002). Ineffective 
clearance by both innate and acquired immune responses leads to chronic infection, 
establishing mucoid P. aeruginosa as the major pathogen of CF airway disease (Lyczak 
et al, 2002). 
One other key aspect of the pathogenesis of chronic lung infection in CF is the ability of 
P. aeruginosa to grow as a biofilm, which increases bacterial resistance to phagocytic 
killing and antibiotics (Meluleni et al 1995). Biofilms, which are microcolonies of 
bacteria normally attached to a surface and encased in a biopolymeric matrix, form 
within the airway and protect the bacteria from host immune factors and antimicrobial 
agents  (Mah and O’Toole, 2001; Dunne et al 2002, Parsek and Singh, 2003). Mucoid-
microcolony formation may have profound effects on the ability of the host to cope with 
the pathogen. Impaired phagocytosis, not capable of clearing the organism has been 
suggested (Krieg ey al., 1988, Meshulam et al 1982, Cabral et al 1987). As a result, the 
large numbers of neutrophils are attracted by inflammation mediated chemotaxis, with 
the ultimate consequence of lung damage directly from excessive neutrophil elastase 
activity and indirectly from immune system-mediated tissue damage resulting indirectly 
from immune complexes (Lucey et al 1985, Bruce et al 1985). Once this stage is 
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reached it is impossible to clear P. aeruginosa from the lungs. However, evidence from 
the analysis of explanted lungs from infected CF patients suggests that P. aeruginosa 
form mucoid aggregate biofioms, rather than surface-attached biofilm (Bjarnsholt et al 
2009). In addition, mucoid and non-mucoid variants of P. aeruginosa often co-exist in 
chronically infected patients, suggesting that the adaptive behavior is not as simple as a 
switch of the whole population from non-mucoid to mucoid (Mowat et al 2011). 
Quorum sensing (QS) is a cell density monitoring mechanism, and is a generic 
phenomenon described in many bacteria.  Bacteria are able to sense their own 
immediate environment and react appropriately; however QS gives them the ability to 
sense their own cell density and to communicate with each other, and behave as a 
population instead of individual cells (Fothergill & Winstanley 2009). In P. aeruginosa 
QS has been widely studied because of its importance in the control of many virulence 
factors. P. aeruginosa uses two signaling system known as a las and rhl systems for QS. 
It has been suggested that QS plays a pivotal role in the initial stages of infection, but 
that its role in pathogenicity diminishes over time. Some studies have highlighted the 
accumulation of mutations within P. aeruginosa populations over time, potentially 
leading to loss of virulence (Schaber et al 2004; Smith et al, 2006). In particular, it has 
been proposed that lasR mutants, defective in QS, occur as an adaptation in chronic 
infections (D'Argenio et al, 2007), and that the QS system may have a negative impact 
on the organism's long-term fitness (Heurlier et al 2006). Bollinger et al. also showed 
that QS regulation of gene expression in P. aeruginosa was complex, dynamic and 
dependent on the growth state of the cells and nutritional factors (Bollinger et al 2001). 
They further suggested a role for QS products in negative regulation of gene expression 
in biofilm formation. There is some evidence that QS plays an important role in 
viability of P. aeruginosa in anaerobic biofilms (Winstanley et al 2009), though it 
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seems likely that there are two probably independent, pathways to biofilm formation in 
P. aeruginosa: QS-dependent or alginate dependent forms independent of each others 
existence.  
Although many of the virulence factors controlled by QS (such as secreted elastase, 
protease, pyocyanin, cyanide, rhamnolipid) are considered to be more relevant to acute 
infections, and lasR mutants are common in CF populations of P. aeruginosa, both 
secreted virulence factors (such as pyocyanin) and QS signaling molecules can still be 
detected in the sputa of chronically infected CF patients, suggesting that QS may play 
an important role beyond the early stages of infection (Fothergill & Winstanley, 2009). 
It is apparent that the acquired host immune response to mucoid P. aeruginosa is 
ineffective at eliminating this pathogen. This ineffective response most likely 
contributes significantly to the inflammatory process that damages the lungs of CF 
patients. It is hypothesized that immune responses to the alginate antigen of mucoid P. 
aeruginosa consist mostly of antibodies that fail to mediate opsonification mediated 
phagocytic killing of the organism: so-called nonopsonic antibodies. Although these 
nonopsonic antibodies are found in all humans and are not unique to CF patients, the 
general titres are higher in CF patients (Pier et al 1987, Ames et al 1985). CF patients 
clearly do produce antibodies that can mediate the opsonification mediated killing of 
mucoid P. aeruginosa, but specificity to the alginate antigen is lacking (Parad et al 
1999). In an in vitro biofilm model these non-alginate antibodies have failed to 
demonstrate the killing of mucoid P. aeruginosa (Meluleni et al 1995), potentially 
explaining their lack of effectiveness at protecting CF patients from chronic P. 
aeruginosa infection. However in some patients there are naturally occurring opsonic 
antibodies to alginate generated by an unknown mechanism that seem to have a better 
response in fighting these alginate antigens. However vaccinations of humans with such 
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antigens generated from mice/ rabbit models have not consistently demonstrated 
protective antibodies (Pier et al 1994) demonstrating this defect in our innate immune 
mechanisms in fighting alginate antigens. 
1.12 Epidemic strains in CF 
a) Europe and worldwide 
In the last two decades several CF clinics worldwide have reported the presence of 
transmissible P. aeruginosa strains (Fothergill et al 2012).  P. aeruginosa is an 
organism commonly found in the environment and capable of surviving in various 
niches. In general, each CF patient within a cohort will acquire a different strain and the 
acquisition of P. aeruginosa in CF patients has generally been attributed to the 
environment, although there is little direct evidence to confirm or dispute this. Detailed 
analyses of several large collections of isolates from both environmental and human 
samples have suggested that the wider population of P. aeruginosa has a largely non-
clonal but epidemic structure, with some dominant clones present (Wiehlmann et al 
2007, Pirnay et al 2005). For example, the “clone C” strain has a worldwide distribution 
and has been found in CF patients and the CF environment, as well as in geographically 
distinct areas and associated with a wide variety of clinical outcomes (Romling et al 
2005).  Although CF patients normally have unrelated strains of which the original 
source remains unknown, initial indications of cross infection were reported by a 
Danish CF centre, where a P. aeruginosa strain identified in 1973 (low proportion) by 
phage-typing was isolated in 1986 in 42% of the patient population; by 1986 this 
particular strain was noted to be multiresistant (Pedersen et al 1986). Selective use of 
antibiotics and patient isolation was suggested based on this centre’s experience. The 
argument for isolation was strengthened by yet another Danish study whereby a winter 
camp of children with CF resulted in cross infection of all the attendees with a clonal 
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strain of P. aeruginosa, confirmed by pulsed field gel electrophoresis (PFGE) (Ojeniyi 
et al 2000). Various other epidemic strains have now been identified in CF clinics. For 
example, epidemic strains have been reported in several CF clinics in Australia. 
(Armstrong et al 2003, Bradbury et al 2008). There have been at least five different 
epidemic strains reported in Australia, known as Australian epidemic strains (AES) 1-3 
and Sydney strains S1 and S2. AES-1 and AES-2 were described in Melbourne and 
Brisbane respectively (Armstrong et al 2003, Bradbury et al 2008, O'Carroll et al 2004, 
Tingpej et al 2007). AES-1 was found in both adult and paediatric CF populations in 
both Melbourne and Brisbane, and resulted in higher hospitalizations and mortality 
among those with chronic infection (Tingpej et al 2010).  AES-2 is much less common 
and has been associated with increased antibiotic resistance and a fall in lung function. 
AES-3 is a strain found in Tasmania. Patients harbouring AES-3 suffered significantly 
more exacerbations requiring hospitalization and increased multi-antibiotic resistance 
compared with other strains (Bradbury et al 2008). These strains have also been isolated 
in CF centres in the Czech Republic and New Zealand (Nemec et al 2010, Schmid et al 
2008). Gene expression characteristics during biofilm and planktonic growth have been 
analysed for strains AES-1 and AES-2 showing enhanced biofilm formation and 
upregulated type III secretion system genes respectively (Manos et al 2009, Manos et al 
2008). These virulence factors have been cited as plausible explanations for success of 
these strains.  
There have been other transmissible strains described in Norwegian and Dutch CF 
centres. In 1995, in a  Dutch study cross-infection after a summer camp was found to be 
negligible (<2%), and authors advocated free intermixing of children with and without 
P. aeruginosa. Indeed, the authors concluded that the risk of cross infection was trivial 
compared to the joys of a summer camp (Hoogkamp et al 1995). However another 
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Dutch group described the risk of transmission among CF children attending summer 
camps as considerable following the finding of two (type 18 and 23) subtypes of P. 
aeruginosa in previously uninfected children, following which segregation measures 
were instituted (Brimicombe et al 2008). Details regarding the morbidity caused by 
these strains or plausible reasons for transmissibility have not been reported.  
A similar sequence of events has been reported from Canada where Speert et al (2002) 
reported an “extremely low risk “ of transmission of P. aeruginosa between patients. 
Their conclusions were based on evaluation of sputum isolates from a CF clinic in 
Canada. Of the 157 genotypes isolated from 174 patients evaluated by PGFE, 123 were 
found to be unique to individual patients. A total of 34 types were shared by more than 
one patient; epidemiological evidence linked these individuals only in the cases of 10 
siblings and 2 unrelated patients. They concluded that there was no significant evidence 
of cross infection or transmissibility in these patients.   However two other studies have 
demonstrated evidence of epidemic strains in Canada. In the first study (Beaudoin et al 
2010) , two clonal strains of P. aeruginosa, type A and type B, were found to infect 
more than 20% of CF patients in Ontario, Canada. Four isolates of each type were 
subjected to further analysis. All 8 isolates expressed high levels of antibiotic resistance 
Subsequently, in 2010 Aaron et al reported 25% infection with clonal strains A and B 
(Aaron et al 2010). Interestingly, strain A was found to be genetically similar to the 
Liverpool Epidemic Strain (LES) strain (see next section). Compared with patients 
infected with unique strains of P. aeruginosa, patients infected with the LES (strain A) 
or strain B had similar declines in lung function, but the 3-year rate of death or lung 
transplantation was greater in those infected with the LES. This was unequivocal 
evidence of presence of a well-studied epidemic strain, which demonstrated adverse 
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outcomes in infected patients. More recently, another transmissible strain (the Prairie 
Epidemic Strain, PES) has also been described in Canada (Workentine et al 2013). 
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b) The LES in the UK: 
Evidence of an epidemic strain in UK CF clinics was first brought to light by Cheng et 
al. (Cheng et al 1996) at a Liverpool paediatric CF clinic. 77% of children in this clinic 
showed presence of isolates resistant to ceftazidime, when only a handful of these 
children had ever had been given ceftazidime. Using genomic fingerprinting techniques 
it was demonstrated that 90 % of these isolates were the same strain of P. aeruginosa, 
now known as the Liverpool Epidemic Strain (LES), indicating the presence of an 
epidemic strain in this CF population that exhibited some antibiotic resistance. 
Suppression subtractive hybridization was used to identify sequences present in the LES 
but absent from other strains of P. aeruginosa (Parsons et al 2002).  This technique was 
then used to develop a diagnostic PCR test for identification of the strain from colonies 
or directly from sputum samples (Parsons et al 2002, Panagea et al 2003).  Evidence for 
the adverse effects of chronic infection with this strain were first demonstrated by Al –
Aloul  (2004), who prospectively followed a cohort of 12 patients chronically infected 
with LES for 5 years and demonstrated that chronic infection with the LES causes 
increased annual loss of lung function  (mean FEV1 difference between groups −4.4% 
(95% CI −8.1 to −0.9; p<0.02)) and poor nutrition (mean BMI 19.4 v 22.7, p<0.02). 
FEV1 and BMI have been proven as important indicators of the health status in patients 
with CF (Al-Aloul et al 2004). Deterioration in these important predictors was the first 
evidence that LES adversely affects the health of CF patients.  However this study only 
included a small number of patients at a single centre in UK. The LES had also been 
reported to show some unusual features not previously reported in P. aeruginosa strains 
in CF.  In a study by McCallum et al  genotypic identification uncovered evidence of 
superinfection by the LES strain whereby the LES was able to replace previously 
established unique strains of P. aeruginosa (McCallum et al 2001). No evidence of 
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environmental contamination was found, but all patients became super-infected after 
contact with colonized individuals during inpatient stays. This phenomenon was noted 
to affect healthy individuals as well. 
McCallum et al. (2002) reported that the LES was able to cause infection in the 
previously healthy parents of a patient with CF (McCallum et al 2002). Once infected 
with the LES, these previously healthy individuals had hospitalization and required 
treatment with intravenous antibiotics repeatedly. LES has also been shown to spread 
from an infected individual to a pet cat (Mohan et al 2008).  
In a nationwide survey to establish the distribution of P. aeruginosa strain genotypes 
among CF patients in the UK, the LES was found to be the most prevalent strain, 
accounting for over 11% of isolates from over 120 hospitals (Scott & Pitt, 2004).  
Fluorescent amplified fragment length polymorphism (FAFLP) analysis revealed some 
microheterogeneity among strains of the LES genotype. This microheterogeneity may 
indicate the adaptations this strain has been undergoing over time to survive in the 
hostile environment of CF lungs. This report was the first indication to suggest that the 
LES was widely transmissible and that cross-infection with P. aeruginosa has occurred 
both within and widely between CF centres in England and Wales. A more recent study 
confirmed that the LES remains widespread amongst the UK CF community (Martin et 
al 2013). Studies up to now had only demonstrated that the LES is transmissible and 
that chronic infection with LES could worsen the general health of the individuals. 
These previous studies were largely limited to the UK, and mostly from a single centre 
with a small number of patients. There had been no evidence from elsewhere or 
indicators to suggest that infection with LES leads to increased mortality. However, the 
study by Aaron et al. (2010), focusing on the LES-like strain in Canada, demonstrated 
just this. A 3-year prospective observational cohort study of adult patients cared for at 
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CF clinics in Ontario was carried out with regular sputum genotyping. 15% patients in 
this centre were found to be infected with a LES-like strain. In patients infected with the 
LES, the 3-year rate of death or lung transplantation was significantly greater than those 
infected with unique strains.  
c) Other epidemic strains in the UK 
Given the emerging evidence from CF centres in the UK for the presence of 
transmissible epidemic strain, which had adverse effects on the health of the CF 
population, detailed multi-centre surveys were carried out. To assess the prevalence of 
such strains in UK CF centres. Scott & Pitt (2004) undertook genetic analysis of sputum 
samples from over 120 hospitals. Although the majority of patients harbored unique 
strains, there was evidence of several epidemic strains. 11% of all isolates from over 15 
centres in England were identified as the LES. However, other abundant strains, such as 
Midlands1, Manchester Epidemic Strain and clone C were identified. 
Midlands1 strain: this was the second most prevalent strain after LES in the survey 
conducted by Scott & Pitt (2004). In a further study by Chambers et al. (2005) this 
strain was found in 30% of individuals at one CF centre in UK. However this strain was 
not found to have adverse effect on patient’s health compared to non-epidemic P. 
aeruginosa or to have enhanced antibiotic resistance. No further studies regarding this 
strain have been reported.  
Manchester strain: Jones et al (2004) found 14% of patients with chronic P. 
aeruginosa had isolates with similar genotypes at their centre in Manchester. The 
shared isolates showed unusual phenotypic characteristics and resistance to a number of 
antipseudomonal antibiotics. This was the first report suggestive of cross-infection by a 
multiresistant P. aeruginosa strain at this centre. An 8 year prospective observational 
study by Jones et al (2010) demonstrated that patients infected with epidemic strains 
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required more intravenous antibiotic treatment requirement and hospitalization without 
any fall in lung function, BMI or increase in mortality. 
Other Epidemic strains: 
There have been isolated reports of epidemic strains in various geographically diverse 
regions of UK. For example, in Sheffield the MR strain was identified (Edenborough et 
al 2004), and in Leeds a colistin resistant transmissible strain was reported (Denton et al 
2002). In both of these cases there was a need for increased antibiotic requirement but 
without any other adverse effects reported for patients. 
1.13 Spread of epidemic strains:  
Numerous studies have attempted to identify the initial source of P. aeruginosa in CF 
patients, but it still remains unknown for most patients. P. aeruginosa can survive for 
prolonged periods. Different phenotypic variants of P. aeruginosa exhibit different 
periods of survival on inanimate objects. In one study it was reported that non-mucoid 
strains suspended in saline could survive on dry surfaces for 24 h, whereas mucoid 
strains could survive 48 h or more (Doring et al 1996, Zimakoff et al 1983), and some 
strains such as the LES, suspended in the sputum of CF patients, can survive on dry 
surfaces for up to 8 days (Doring et al 1996). 
 P. aeruginosa has been recovered from both inpatient and outpatient environmental 
sources.  Various strains exhibiting genetic variability have been isolated from 
immediate environment of CF patients (Doring et al 1996, Romling et al 1994), toys, 
baths, and hand soaps (Zimakoff et al 1983), and lung function equipments and hospital 
drains (Speert et al 1987).  Isolation of such strains from the environment however 
doesn’t help to identify the source despite the matching characteristics of the strains 
seen in the environment and healthcare setting (Wolz et al 1989, de Soyza et al 2001, 
Doring et al 1996).  However several other studies have not been able to detect any 
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environmental contamination in a centre where there was evidence of epidemic strains 
despite multiple cultures (McCallum et al 2001). There has been direct evidence of P. 
aeruginosa strains in cultures taken from hands of healthcare professionals and 
nebulizers used by patients suggestive of indirect sources of spread of such strains 
(Speert et al 2002, Doring et al 1991). Other potential sources of P. aeruginosa include 
whirlpools, hot tubs (Berrouane et al 2000), swimming pools, or dental equipment 
(Jensen et al 1997). Droplet transmission has been demonstrated by isolating P. 
aeruginosa from agar plates placed 1.25 to 3 ft from a coughing CF patient (Doring et 
al 1996, Zimakoff et al 1983). Air samples from CF clinics and hospital rooms have 
yielded contradictory results (Speert et al 1987, Wolz et al 1989) and therefore no clear 
conclusions can be drawn regarding environmental spread. 
 Evidence of patient-to-patient transmission of P. aeruginosa has been studied 
extensively. The best documentation of shared strains of P. aeruginosa among CF 
patients has been noted between siblings with CF (Grotheus et al 1988, Wolz et al 
1989). There have been several reports of shared strains of P. aeruginosa among CF 
patients linked to mingling of patients in recreational camps (Fluge et al 2001, Ojeniyi 
et al 2000).  
Panagea et al. (2005) conducted an environmental survey at the Liverpool adult CF 
clinic to determine the extent of environmental contamination with the LES, and to 
identify possible reservoirs and routes of cross-infection. Samples were collected from 
staff, patients and the environment commonly used by the patient (drains, bath tubs, 
showers, dry surfaces, respiratory equipment and air in both inpatient ward and 
outpatient clinic). P. aeruginosa strains were tested by using PCR assays specific for 
the LES. The LES was isolated from patients' hands, clothes and bed linen. 
Environmental contamination with LES was only detected in close proximity to 
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colonized patients (external surfaces of their respiratory equipment, and spirometry 
machine tubing and chair) and was short-lived. No environmental reservoirs were 
found. LES was detected in the majority of air samples from inside patients' rooms, the 
ward corridor and the outpatient clinic. Survival of LES on dry surfaces was 
significantly longer than that for some other strains tested.  
A similar survey of the CF environment was carried out in the Manchester CF clinic, 
including room air sampling, and identification of individual P. aeruginosa by 
genotyping (Jones et al 2005). The typing patterns were compared with those of 
epidemic strains responsible for cross infection among the patients. Epidemic P. 
aeruginosa strains were isolated from room air when patients performed spirometric 
tests, nebulisation, and airway clearance, but were not present in other areas of the 
inanimate environment of the CF centre. These studies do suggest that aerosol 
dissemination may be the most important factor in patient-to-patient spread of epidemic 
strains of P. aeruginosa in CF centres with cross infection. 
1.14 Controversies in morbidity due to epidemic strains 
Various studies have been carried out to assess the impact of infection with 
transmissible strains with respect to patient morbidity. In one study, Al-Aloul et al. 
(2004) looked at two cohorts of CF patients attending the Liverpool CF service whose 
LES status was identified by genomic fingerprinting technique. 12 adult CF patients 
infected with LES were matched in 1998 for age, spirometric parameters, and 
nutritional state to those without and their clinical course was followed for 5 years.  
Patients with LES had a greater annual loss of lung function than those without (mean 
difference between groups 24.4% (95% CI –8.1 to 20.9; p=0.02)), and by 2002 their 
percentage predicted forced expiratory volume in 1 second (FEV1) was worse (mean 
65.0% v 82.6%, p=0.03). Their nutritional state also deteriorated over the study period 
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(mean difference between groups in body mass index 20.7 (95% CI –1.2 to 20.2; 
p=0.01)), such that by 2002 they were malnourished compared with LES negative 
patients (mean BMI 19.4 v 22.7, p=0.02) (Al-Aloul et al 2004). This illustrates that 
chronic infection with the LES strain in CF patients confers a worse prognosis than 
infection with other non-LES strains. However this was a study, which was conducted 
with a small study population. The study by Chambers et al. (2005) done at a different 
CF centre in the UK demonstrated similar findings in terms of the morbidity caused by 
the LES.  Patients infected with the LES exhibited enhanced antibiotic resistance, 
increased need for intravenous antibiotics, renal failure (Al Aloul et al 2005) and 
hospitalization. These studies demonstrate that the LES is a problem in more than one 
centre in the UK. More recently there has been evidence to suggest that LES is a 
problem not just limited to the UK. There has been a Canadian study reported by Aaron 
et al.  (2010) who studied 446 patients with CF. 102 were discovered to be infected with 
one of two common transmissible strains of P. aeruginosa.  15% patients in this centre 
were found to be infected with a strain genetically similar to the LES. Compared with 
patients infected with unique strains of P. aeruginosa, patients infected with the LES 
(strain A) had a rapid decline in lung function (difference in decline in percent predicted 
FEV1 of 0.64% per year [95% CI, −1.52% to 2.80% per year] and 1.66% per year [95% 
CI, −1.00% to 4.30%], respectively). The 3-year rate of death or lung transplantation 
was also greater in those infected with the LES (18.6%) compared with those infected 
with unique strains (8.7%) (adjusted hazard ratio, 3.26 [95% CI, 1.41 to 7.54]; P=.01) 
(Aaron et al 2010). This study is further evidence of the fact that the LES causes 
increased morbidity and mortality in adult CF patients. This study was conducted with a 
larger number of patients compared to the previous study, with a long period of follow 
up demonstrating the hazards of chronic infection with LES. These studies have 
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conclusively proved that chronic infection with LES causes a rapid decline in health 
status in these individuals leading to higher healthcare needs and mortality. However, 
this problem is not universal with other known epidemic strains. It has been suggested 
that changes to infection control programmes in relation to frequent epidemic clones 
should be based on their frequency, virulence across all age groups and mode of 
acquisition (Fothergill et al 2012). The Australian epidemic strain-1 (AES-1) and AES-
2 are common in CF clinics in mainland eastern Australia, but not in the environment.  
A large CF clinic in Australia examined 258 P. aeruginosa isolates from 112 
participants using genotyping by PFGE. Ninety-eight patients were followed up for 1 
year and associations sought between infection with a frequent epidemic clone, clinical 
outcome and antibiotic resistance. Four frequent P. aeruginosa epidemic clones affected 
almost 50% of participants.  Three of these four were associated with increased 
exacerbations and hospital-admission days, but only one strain showed increased 
resistance to antibiotics (Armstrong et al 2003). Patients infected with another epidemic 
strain from Canada ST-439 not previously identified in patients with CF, were followed 
up for a period of 3 years and there were no greater risk of hospitalization or lung 
transplant. (Aaron et al 2010). Other Epidemic strains isolated in UK (Tubbs et al 2001, 
Denton et al 2002, Edenborough et al 2004) or worldwide (Fluge et al 2001, Speert et al 
2002) haven’t shown evidence of morbidity or increased mortality, which is further 
evidence to support the assumption that not all epidemic strains are harmful.  Hence 
assertions that epidemic strains are always harmful and that measures should be 
implemented to protect patients with such chronic infections do not hold true 
universally.  
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1.15 Previous studies describing phenotypic and genotypic characteristics of the 
LES 
It has been demonstrated in infection models that there is a big variation in the virulence 
characteristics of various sub-types of the LES. Four different LES subtypes displayed 
varied virulence in a mouse respiratory infection model (LES431, LESB65, LES400, 
LESB58), with LES431, which is associated with the spread of infection to the non-CF 
parent of a CF patient, being by far the most virulent (Carter et al 2010). It has been 
shown that some LES isolates, including LES431, have enhanced expression of 
virulence factors controlled by QS (Salunkhe et al 2005). In particular, such isolates 
produce high levels of pyocyanin (Fothergill et al 2007). Pyocyanin and its precursor 
phenazine 1 –carboxylic acid (PCA) have a number of toxic effects on patients with CF. 
(Fothergill and Winstanley, 2009)  For example, pyocyanin inhibits the beating of 
human respiratory cilia in vitro and induces neutrophil apoptosis and impairs neutrophil 
induced host defenses. Increased concentration of pyocyanin results in further reduced 
expression of CFTR in lung and nasal epithelium, further potentiating the genetic 
effects of CFTR. Certain genetic mutations within LES variants such as the LES 431 
lead to an up-regulated QS regulon as well as other transcriptional changes (including 
transcription of AmpC beta-lactamase), characteristics that could contribute to the 
success of the LES. (Salunkhe et al 2005).  Some phenotypic features such as ability to 
survive on dry surfaces for prolonged period may also explain its success. 
The earliest archived isolate of the LES (named LESB58, from 1988) was genome 
sequenced in 2009 (Winstanley et al 2009).  The main genomic differences between the 
LES and other strains of P. aeruginosa are due to the presence in the genome of a 
number of genomic islands and prophages, and it was shown that some genes within 
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these prophage regions play an important role in the competitiveness of the strain in a 
rat model of chronic lung infection. Hence prophage regions are also implicated in the 
success of this strain. 
Adaptations typical of P. aeruginosa during CF infections have been mentioned earlier.  
However, recently it has become apparent that populations of the LES harbor extensive 
phenotypic diversity during chronic infections in the CF lung.  Phenotypic and 
genotypic diversity in LES populations has been studied by analysis of multiple isolates 
per sputum sample (Fothergill et al 2010, Mowat et al 2011). These studies have 
revealed extensive within-population variations in the phenotypes of the LES, including 
auxotrophy, hypermutability, production of pyocyanin and susceptibilities to a range of 
antibiotics.  Each patient population is diverse but also dynamic (Mowat et al 2011).  
This has important consequences with respect to the potential for adaptation (because P. 
aeruginosa populations can harbor extensive diversity, enabling them to adapt quickly), 
and the relevance of antimicrobial susceptibility tests based on single isolates. The 
considerable diversity in antibiograms obtained when analyzing multiple isolates from 
the same CF sputum sample suggests that results based on single isolates may be flawed 
(Mowat et al 2011). This diversification could be important in the emergence of 
subtypes better able to exhibit transmissibility, which may be due to improved ability to 
colonise, and replace established P. aeruginosa (superinfection), enhanced 
survival/persistence in the environment, or a combination of these.  At the start of the 
project described in this thesis, it was not known whether this diversification was 
widespread or a particular feature of the LES.  Subsequent publications suggest the 
former (Workentine et al 2013). 
As a part of the work undertaken here, I aim to address the issue of whether 
diversification is a common feature of P. aeruginosa populations in CF.  In addition, I 
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investigate other reasons that may be contributing to the persistence of LES.  Although 
there have been studies proving an association between the LES and increased patient 
morbidity, there has been no study proving that the LES exhibits enhanced antibiotic 
resistance. In addition, there are unanswered questions regarding how chronic infection 
with the LES affects an individual’s Health Related Quality of Life (HRQL). Intuitively 
it may appear that chronic infection with LES should adversely affect both of these 
factors, but so far it has not been studied or reported. It may also be the case that 
institutions with patients chronically infected with the LES have higher economic and 
healthcare resource implications; however, this has also not been reported in the past. 
Since adverse effects of the LES are now known, our CF centre has instituted 
segregation measures to limit its numbers and to protect patients with no previous P. 
aeruginosa growth from the harmful health hazards resulting from acquisition of the 
LES. It is however unknown if such segregation measures are useful in limiting the 
numbers of LES infection and prevention of superinfection.  
1.15 Aims of this study. 
1. To compare the health related quality of life of LES-infected patients with those CF 
patients infected with non LES P. aeruginosa. 
3. To compare antibiotic resistance exhibited by the LES with the resistance of unique 
(non LES) P. aeruginosa strains. 
3. To determine whether extensive diversification is a common feature of P.  
aeruginosa populations during respiratory infections in CF.  
4. To analyze the healthcare costs associated with chronic infection with the LES. 
5. To review the results of cohort segregation policies at the Liverpool adult CF unit in 
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limiting the spread of the LES strain. 
1.16 Format of the thesis 
The thesis contains a general introduction chapter (Chapter 1) at the start and then a 
general discussion chapter (Chapter 7) at the end.  The other chapters (Chapters 2 – 6) 
are in the form of five studies written for publication:   
 The work presented in chapter 2 has been published JR Soc Sh Rep 2012; 3:12. 
DOI 10.1258/ shorts.2011.011119 
 The work presented in chapter 3 has been published in Journal of Cystic 
Fibrosis, volume 11, issue 3, May 2012 173-179 
 The work presented in chapter 4 has been published in Journal of Cystic 
Fibrosis, volume 12, issue 6, December 2013, pages 790-793 
 The work presented in chapter 6 has been published in J R Soc Sh Rep 2013; 4:1 
DOI 10.1258/shorts.2012.012018 
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Chapter 2 :  A Cohort Study of Health Related Quality Of Life Outcomes in 
Adult CF patients chronically infected With Transmissible Pseudomonas 
aeruginosa Strains. 
Authors:  Abdul Ashish, Matthew Shaw, James McShane, Martin J. Ledson, 
Martin J. Walshaw 
 
2.1 Abstract: 
 
 
Background: Although adult CF patients harbouring epidemic Pseudomonas aeruginosa 
(Psa) strains (particularly the Liverpool epidemic strain, LES) have a rapid decline in 
physical markers of disease severity and increased mortality compared to other CF 
patients, it is not known if they also have a poorer health-related quality of life 
(HRQoL).  
 
Methods: 157 clinically stable adult CF patients (93 with transmissible Psa [median age 
26 years (IQ range 26-31), 38 females]; 44 with unique Psa [22 (20-28), 16 females], 
and 20 without Psa infection [21(19-29), 9 females]) completed a validated CF HRQoL 
questionnaire (CFQ-UK, Teen/Adult revised, version 1) prior to being seen by a health 
professional at a routine CF clinic. Those with Burkholderia cepacia and atypical CF 
were excluded. Kruskal–Wallis and Mann Whitney’s U tests were used to analyse the 
data.  
 
Results:  Patients infected by transmissible Psa strains had worse physical functioning, 
respiratory symptoms, treatment burden, vitality, role, health perception and emotion 
than those with unique Psa strains(p<0.01), and significantly poorer physical 
functioning, respiratory symptoms, treatment burden, body-image, weight, role, and 
emotion than those without any Psa infection (p<0.05). Furthermore, in a matched 
cohort of 39 patients, those with LES infection reported significantly worse physical 
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functioning, treatment burden, respiratory symptoms and health perception than those 
with unique Psa infection (p<0.02). 
 
Conclusion: Chronic infection with transmissible Psa strains, particularly LES, 
confers a worse quality of life in adult CF patients. Coupled with the established poorer 
clinical outcome, this reinforces the need to prevent the spread of such strains in CF 
community. 
 
2.2 Introduction: 
Cystic fibrosis (CF) is the commonest potentially lethal inherited disease in the Western 
World. Although it is incurable, survival in CF has improved over the years and current 
epidemiological data suggest that the average life expectancy of an individual born with 
CF in the UK is now 38 years. (1833 UK 2008) However, this is at the expense of a 
high treatment burden, particularly in those chronically infected with Pseudomonas 
aeruginosa (Psa), which is known to confer, increased morbidity and mortality (Henry 
et al 1992, Kerem et al 1990) and may therefore diminish their quality of life (QoL).  
The WHO has defined health as “a state of complete physical, mental and social well 
being and not merely the absence of disease or infirmity” (WHOQOL 1995), and 
therefore, in CF managing the patient’s psychological and psycho-social wellbeing, 
which influence their QoL, is as important as managing the physical aspects of their 
disease.  
Health-related quality of life (HRQoL) questionnaires can describe health outcomes in 
ways that are meaningful to patients and families as well as to healthcare professionals, 
and recently a disease-specific HRQoL questionnaire (the CFQ-US) has been developed 
for patients with CF, and a UK version of this (the CFQ-UK) has been validated for use 
without the loss of its psychometric properties. (Quittner et al 2005)  
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Although several studies have looked at QoL in CF, few have investigated how an 
individual patient’s disease state, particularly infection with Psa, may impact on this. 
Recently, transmissible Psa strains have been identified, the most important of which is 
the Liverpool Epidemic Strain (LES) (Cheng et al 1996) now widespread throughout 
UK CF centres (Scott & Pitt, 2004), which has also been reported in Canada (Aaron et 
al 2008). LES is associated with a worse clinical outcome (Al-Aloul et al 2004). We 
have a high incidence of LES Psa infection in CF patients attending our adult clinic: we 
were therefore interested to look at the effect of Psa infection, and in particular that due 
to LES, on the quality of their lives and used the CFQ-UK for this purpose. 
  
2.3 Methods:  
All 204 patients in a clinically stable state (i.e. no exacerbation within the previous 4 
weeks) attending a routine outpatient visit between August 2009 and March 2010 
formed the potential study population. Those with atypical CF or chronically infected 
with Burkholderia cepacia complex were excluded.  Of the remaining 168 patients, 11 
(5%) refused to take part. Following informed consent, 157 patients completed the 
CFQ-UK (Teen/Adult revised, version 1) (Quittner et al 2005) prior to being seen by a 
healthcare professional. Clinical details (sputum microbiology, lung function, 
nutritional state, and diabetes mellitus) were retrieved from the case records to aid 
subsequent data analysis. The regional ethics committee approved this study. 
(Study Ref no -09/H1013/52: Oldham, Tameside & Glossop & Salford & Trafford 
Research Ethics Committees) 
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2.3.1 Psa Infection state 
All patients submit microbiological samples at every clinic visit/inpatient stay: chronic 
infection with Psa is defined by at least 3 positive sputum samples within a 6-month 
period. (Hoiby et al 2000) Our unit has pioneered Psa genotyping methodology in CF, 
and we regularly genotype the Psa isolates from our patients to aid cross infection 
control measures within the clinic: those without known LES infection undergo 
genotyping using PCR every 3 months to identify unique and other transmissible Psa 
strains (Fothergill et al 2008), whilst those infected with LES undergo a genotypic 
check (using PCR and primers PS21 & F9) (Smart et al 2006) on a yearly basis. Using 
this system, we are aware of the Psa genotypes infecting our CF patients at all times.  
Based on this, we divided the surveyed patients into 3 groups: 93 with LES (all infected 
prior to transfer from the paediatric sector), 44 with other Psa strains (43 infected prior 
to transfer from the paediatric sector), and the remaining 20 without Psa infection or 
with persistently negative cultures (6 cases had undergone successful Psa eradication 
since transfer from the paediatric sector) (Table 2.1).  
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Table 2.1: Total study population demographics (n=157) 
 
 
 
 
  
 
Psa Strain 
No Psa Infection 
LES  Other  
Number of patients 93 44 20 
Females (%) 38 (51) 16 (38) 9 (48) 
Median age, years 
( IQR) 
26 (26-31) 22 (20-28) 21 (19-29) 
Mean FEV1% 
(SD) 
65 (23) 69 (23) 77.8 (26) 
Mean BMI 
(SD) 
21.7 (3.5) 22.6 (3.6) 
25 (4.8) 
 
Diabetes (%) 46 (49) 13 (29) 2 (10) 
Enteral feed  5 1 0 
TIVAD (%) 45 (48) 8 (18) 3 (15) 
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2.3.2 Statistical analysis and patient matching 
The Kruskal-Wallis test was used to determine differences between the 3 groups on all 
12 CFQ-UK domains, and where significant differences were noted individual 
comparisons between groups were made using the Mann-Whitney U test.  
In our initial unmatched cohort although there were no significant differences in age or 
FEV1 between groups, patients chronically infected with LES had a higher disease 
burden as evidenced by more with CFRD (Cystic Fibrosis Related Diabetes Mellitus), 
TIVAD (Totally Indwelling Venous Access Device) implantation and the use of enteral 
feeding (all p<0.005 compared to other groups). To overcome this, using all available 
patient data we developed a multivariate logistic regression model and generated a 
propensity score for LES group membership (Blackstone et al 2002, Kuss, O 2002) in 
order to allow matching with patients infected with other Psa strains.  A full 
nonparsimonious model was developed that included FEV1, BMI, age and gender as 
independent variables and treatment category as the dependent variable. The goal is to 
balance recorded patient characteristics between treatment groups by incorporating 
everything recorded that may relate to either systematic bias or simply bad luck.  
 
The regression model had an appropriate fit (Hosmer–Lemeshow goodness-of-fit   
12.4 and p=0.13) and acceptable discrimination (c statistic, 0.78) indicating an 
acceptable ability to differentiate between patients with or without LES. We then used a 
macro (available at: http://www2.sas.com/proceedings/sugi29/165-29.pdf) to perform 
propensity-matching.  Before matching, the median propensity scores for patients with 
and without LES were 0.70 and 0.66, respectively (Wilcoxon signed-rank test p=0.036). 
After matching, the the median propensity scores for patients with and without LES 
were 0.67 and 0.66, respectively (Wilcoxon signed-rank test p=0.81) 
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Using this technique we were able to match 39 patients chronically infected with LES 
with 39 patients infected with other Psa strains. We did not attempt to match LES 
patients with those without Psa since Psa infection per se is known to confer a worse 
morbidity and mortality. 
A p<0.05 was considered to be significant. All statistical analysis was performed using 
SAS for Windows Version 8.2. 
2.4 Results:  
The demographic details and clinical characteristics of the 157 patients who completed 
the CFQ–UK questionnaire are given in Table 2.1. Patients chronically infected with 
LES had a higher disease burden compared to those with other Psa strains or no Psa 
infection. 
Using the Kruskall–Wallis test, comparison across all 3 groups of patients produced 
significant differences in 9 of the 12 HRQoL domains. Individual comparisons between 
groups using the Mann-Whitney U test across these 9 domains revealed that patients 
harbouring LES infection had significantly worse physical functioning, respiratory 
symptoms, treatment burden, vitality, role, health perception and emotion than those 
with unique Psa strains, and significantly poorer physical functioning, respiratory 
symptoms, treatment burden, body-image, weight, role, and emotion than those without 
any Psa infection. However patients infected with unique Psa strains only reported a 
worse perception of body image than those with no Psa infection (see Table 2.2) 
Table 2: Difference in HRQoL* domains between LES infection, other infection and no 
Psa infection groups: Mann-Whitney U test [median score (IQR)] (*higher scores 
indicate better outcomes) – Unmatched groups Psa 
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Microbiology Other Psa No Psa p 
Physical function 
79 
(58-96) 
75 
(56-94) 
NS 
Role 
83 
(58-100) 
83 
(62-100) 
NS 
Vitality 
58 
(50-75) 
58 
(33-91) 
NS 
Emotion 
80 
(66-93) 
83 
(63-93) 
NS 
Body image 
78 
(55-100) 
100 
(100-100) 
0.008 
Respiratory 
symptoms 
67 
(50-83) 
77 
(67-86) 
NS 
Treatment 
burden 
67 
(55-76) 
72 
(33-83) 
NS 
Health 
perception 
67 
(55-78) 
67 
(0-89) 
NS 
Weight 
100 
(67-100) 
100 
(100-100) 
NS 
LES No Psa p 
58 
(33-87) 
75 
(56-94) 
0.03 
75 
(50-92) 
83 
(62-100) 
0.04 
50 
(33-66) 
58 
(33-91) 
NS 
73 
(53-86) 
83 
(63-93) 
0.05 
67 
(44-100) 
100 
(100-100) 
0.0009 
55 
(39-72) 
77 
(67-86) 
0.0002 
55 
(44-67) 
72 
(33-83) 
0.01 
55 
(33-67) 
67 
(0-89) 
NS 
100 
(33-100) 
100 
(100-100) 
0.01 
LES Other Psa p 
58 
(33-87) 
75 
(56-94) 
0.0003 
75 
(50-92) 
83 
(58-100) 
0.01 
50 
(33-66) 
58 
(50-75) 
0.008 
73 
(53-86) 
80 
(66-93) 
0.02 
67 
(44-100) 
77 
(55-100) 
NS 
55 
(39-72) 
67 
(50-83) 
0.002 
55 
(44-67) 
67 
(55-76) 
0.01 
55 
(33-67) 
66 
(55-78) 
0.01 
100 
(33-100) 
100 
(100-100) 
NS 
Table 2.2 
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Furthermore, in the matched cohort of 39 patients (see Table 2.3), those with LES 
infection reported significantly worse physical functioning, treatment burden, 
respiratory symptoms and health perception than those with unique Psa infection (see 
table 2.4), and 5 further domains (role, vitality, body image, and emotional and social 
functioning) approached statistical significance.  
 
Table 2.3: Univariate Demographics in LES infected and other Psa infected 
- Matched Group 
 
 
Continuous variables are shown as mean (standard deviation) 
Categorical variables are shown as a number (percentage) 
 
 
 
Other Psa infection 
 (n=39) 
LES infection 
(n=39) 
p-value 
Female (%) 14 (37) 11 (28) 0.36 
Age (years) 28 (8) 28 (9) 0.66 
BMI (SD) 22.6 (3.6) 22.3 (3.1) 0.80 
FEV1(SD) 71 (22) 69 (21) 0.77 
Diabetes (%) 11 (28) 18 (46) 0.15 
Enteral feeding 1 2 1.00 
TIVAD (%) 12 (31) 21 (53) 0.66 
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Table 4: HRQoL outcomes* in LES infected and Other Psa infected Matched Groups: Mann-Whitney U test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Higher scores indicate better outcomes 
Variables quoted as median (inter-quartile range) 
 
QoL Dimension 
Other Psa infection 
 (n=39) 
LES infection 
 (n=39) 
p-value 
Physical Function 84 (63 – 100) 72 (33 – 88) 0.02 
Role 84 (67 – 100) 76 (50 – 92) 0.06 
Vitality 59 (50 – 75) 51 (33 – 67) 0.06 
Emotional Function 81 (67 – 93) 74 (53 – 93) 0.07 
Social Function 79 (61 – 83) 68 (50 – 83) 0.07 
Body Image 89 (56 – 100) 68 (44 – 100) 0.09 
Eating 100 (89 – 100) 100 (78 – 100) 0.16 
Treatment Burden 68 (56 – 78) 57 (44 – 67) 0.02 
Health Perception 68 (56 – 89) 57 (33 – 78) 0.01 
Weight 100 (67 – 100) 100 (33 – 100) 0.36 
Respiratory Symptoms 73 (50 – 83) 62 (44 – 72) 0.006 
Digestion 89 (67 – 100) 89 (67 – 100) 0.70 
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2.5 Discussion: 
Although it is known that age, sex, FEV1, nutritional state, the use of indwelling venous devices, 
pulmonary exacerbations and the presence of diabetes can adversely affect the QoL in CF 
patients (Gee et al 2003, Gee et al 2005, Abbott et al 2009), little work has been done on the 
effect of chronic infection in this group. Studies looking at B cepacia infection have given 
variable results. Duff (Duff et al 2002) showed that segregation from other patients caused 
feelings of isolation, anger and of being a microbiological “leper” but did not use objective QoL 
assessment tools, and although Gee (Gee et al 2005) did not demonstrate any excess effect of B 
cepacia infection compared to other organisms, no details of disease severity were recorded and 
the patient numbers were small. 
As regards Psa infection, whilst Goldbeck (2007) suggested that new infection had an 
independent negative effect on QoL, the study was small and did not achieve statistical 
significance. Although previous studies addressing the effect of chronic Psa colonisation have 
failed to show any adverse effects, the study by Britto et al (2004) had poorly matched groups, 
used a generic QoL questionnaire (sf-36) and only a third of the participants were adults, and the 
study by Havermans et al (2009) in 57 adult CF patients did not use patient matching and no 
information regarding Psa strain types was provided.  
To our knowledge this is the first study evaluating the health-related quality of life in a 
substantial number of Psa-infected adult CF patients including those chronically infected with 
the most important such transmissible strain, LES.  For the first time, we have shown that 
infection with LES confers a worse quality of life in CF than infection with other Psa strains and 
those without any Psa, and this was confirmed in matched groups of patients. This is an 
important finding that needs to be heeded by the CF healthcare community. 
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LES first came to light in 1996 at our local paediatric CF centre (Cheng et al 1996), and is now 
widespread throughout UK CF clinics (Scott & Pitt, 2004). It has also been reported at a CF 
centre in Canada. (Aaron et al 2008) It is highly transmissible – it can super-infect patients 
already possessing other Psa strains, (McCallum et al 2001) can spread to non-CF relatives 
(McCallum et al 2002), and also cross-infect other species (Mohan et al 2008). We have a large 
cohort of such patients, mainly inherited from the paediatric sector and have already shown that 
these patients have a poorer prognosis (Al-aloul et al 2004) and increased treatment burden 
(Ashish et al 2010) than other (matched) patients. It is therefore not surprising that these 
individuals also have a poorer quality of life.  
Furthermore, LES-infected patients not only scored more poorly in those domains assessing 
physical well being (physical function, treatment burden and respiratory symptoms) but also in 
those assessing psychological functioning (vitality, emotion, health perception and body image). 
The impairment of physical domain QOL indicators are expected as LES is known to cause a 
more rapid decline in lung function, weight, and increase the need for IV antibiotics, triggering 
the need for extra therapy which in turn results in a higher treatment burden. However, the 
poorer scores in the psychological domain indicators suggest that LES has a more profound 
effect on these individuals than that expressed by physical deterioration alone. This combination 
of poor perceived physical parameters (poor physical function, treatment burden, weight, and 
respiratory symptoms scores) and higher psychological burden (poor vitality, emotion, health 
perception and body image scores) in patients with LES may result in an overall worse HRQoL 
compared to those infected with other Psa strains or without Psa infection.  
However, the cohort of LES-infected patients in our study were older and had poorer pulmonary 
function and had a higher disease burden as evidenced by higher incidence of CFRD, those with 
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TIVAD’s and needing enteral feeds than the remainder, suggesting that at least some of these 
differences in quality of life could be due to this. It was for this reason that we compared 
matched groups, obtained using a validated statistical propensity scoring system.  In this matched 
group of patients infected with Psa strains, those with LES still demonstrated a significantly 
worse perception of physical (physical function, treatment burden, respiratory symptoms) and 
psychological (health perception) well being compared to patients with other Psa strains. 
Furthermore, although other aspects of psychosocial well being (role, vitality, emotional 
function, social function & body image) failed to achieve statistical significance, there were 
strong trends, indicating that these changes are a true reflection of the patients’ LES infection 
status. It was for this reason that we opted not to use alpha correction (e.g. Bonferroni) for group 
matching since the differences between the matched groups (without correction) were close to 
the level of significance: this is highly unlikely to be a chance occurrence.  
In contrast, patients infected with other Psa strains only had an altered body image compared to 
patients without Psa infection, suggesting that acquisition of sporadic Psa may not significantly 
impact on the psychological well being of the individual.  
It has already been shown that depression and anxiety are more common in CF (Riekert et al 
2007) and can adversely affect their QoL: anxious patients report more respiratory symptoms, 
have a poorer perception of their health and treatment burden, and poorer social and emotional 
functioning, whilst those with depression show a poorer body image, eating disturbances and 
emotional functioning. (Haverman et al 2008) Although our study was not designed to address 
the prevalence of anxiety and depression among our patients, it may be that these factors also 
contribute to the poorer QoL outcomes in patients infected with epidemic strains and this merits 
further study. 
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This large cross-sectional QoL study adds further evidence to the poor outcomes associated with 
chronic infection with transmissible Psa strains in CF: those harbouring LES reported worse 
scores across most HRQoL domains compared to patients without such infection.  
There are limitations to our study: we only looked at one centre with a high prevalence of one 
transmissible Psa strain (LES) and used a cross-sectional design, and it may be that the results 
cannot be generalised to other transmissible Psa strains or the CF population at large. 
Nevertheless, LES is the most prevalent transmissible strain in the UK and has already spread to 
units elsewhere, so our findings will be of relevance to many CF clinics. Also, this is the largest 
study of the measurement of QoL in adult CF patients, using a new validated tool, which is 
increasingly being employed in the holistic assessment of this chronic disease group. Although 
longitudinal studies with repeated QoL measurements before and after chronic infection with 
such transmissible epidemic strains are needed to address their true effect on QoL in CF patients, 
our study does highlight the physical as well as psychosocial limitations faced by patients 
infected with such epidemic strains.  
Prevention of cross infection with transmissible strains is essential to ensure better physical and 
psychological outcomes for these patients, and such strategies should be adopted by all CF 
centres. 
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3.1 INTRODUCTION 
Chronic lung infections with Pseudomonas aeruginosa are the most common cause of the 
morbidity and mortality associated with cystic fibrosis (CF). Such infections can persist for long 
periods, during which P. aeruginosa adapts by accumulating mutations that lead to phenotypic 
adaptations, such as the switch to a mucoid phenotype. It has been clear that mutations can lead 
to populations of P. aeruginosa composed of multiple clones with differing antimicrobial 
susceptibility profiles. (Foweraker et al 2009, Fothergill et al 2010)  In a previous study,  
(Mowat et al 2011) we analyzed P. aeruginosa sputum populations from ten CF patients each 
infected with an important transmissible strain, the Liverpool Epidemic Strain (LES)  
(Winstanley et al 2009), which is widespread in the UK and has also been reported in North 
America (Fothergill et al 2012).  We showed, based on 15 different phenotypic and genotypic 
characteristics, that LES populations were highly diverse and dynamic during CF infections 
(Mowat et al 2011).  
Other groups have used genome sequencing or transcriptomics approaches to study sequential 
isolates from infections of CF patients, and demonstrated the accumulation of particular 
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mutations that indicate adaptation to the CF lung in terms of altered or reduced virulence, as well 
as antimicrobial susceptibility (Smith et al 2006, Brago et al 2009, Huse et al 2010).  A recent 
study of strain DK2, infecting multiple patients in Denmark, presented evidence suggesting that 
after the accumulation of mutations during the early stages of infection, a homogeneous 
population of DK2 emerged (Cramer et al 2011).  This appears to contradict our study with the 
LES, suggesting that the maintenance of extensive diversity may be a strain-specific feature of 
infections with the LES.  However, similar analyses using the widely distributed Clone C and 
PA14 strains indicated that diversity may be dependent upon the emergence of hypermutators 
amongst the P. aeruginosa population (Yang et al 2011). 
In this study, we examined the diversity of P. aeruginosa populations in a set of five adult CF 
patients each chronically infected with a different non-LES strain of P. aeruginosa.  We analysed 
sets of 40 isolates of P. aeruginosa from each of two sputum samples per patient for nine 
characteristics, including hypermutability, and susceptibility to commonly used antimicrobials.  
In order to test whether extensive diversification is a feature unique to the LES, or common to P. 
aeruginosa infections of CF patients in general, we compared LES and non-LES populations 
from matched chronically infected adult CF patients using the same set of characteristics. 
3.2 MATERIALS AND METHODS 
3.2.1 Patients and samples 
Sputum samples were collected for routine diagnostic purposes from adult CF patients (CF20-
CF24; Table 3.1) known to be chronically infected (> 5 years) with different non-LES strains 
of P. aeruginosa in 2009-2010.  Strains were genotyped using an ArrayTube system (Wiehlmann 
et al 2007) and identified according to the hexadecimal code generated by this method as 
genotypes 2F82 (CF21), 2C1A (CF22; Midlands 1 strain (Fothergill et al 2008), 0F1A (CF23), 
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C80A (CF24) and AF9A (CF25).  Samples taken during periods of exacerbation were sub-
divided into two categories: beginning of an exacerbation (acute 1), before intravenous antibiotic 
treatment had commenced; typically 3-7 days after admission (acute 2). Exacerbations were 
defined by a clear set of criteria as described previously (Goss et al 2007).  For each patient 
included in this study, one acute 1 and one acute 2 sample was used.  The five patients 
chronically infected with non-LES strains were matched with five LES-infected patients.  All 
patients had been infected with P. aeruginosa for > 5 years (Table 1).  Comparison data for LES-
infected patients was taken from a previous study (Mowat et al 2011).  Patients with similar age, 
lung function (FEV1) and BMI were selected. We had difficulty in exactly matching non-LES 
infected patients to LES-infected patients in all clinical characteristics.  In our experience 
patients infected with non-LES strains of Psa have less aggressive disease, preserved clinical 
characteristics and better overall outcome. Hence, patients infected with non-LES strains for > 5 
years in general had better lung function when compared to patients infected with the LES. Even 
in an institution with caters for approximately 250 adult CF patients we could not recruit non-
LES infected patients with exactly matching clinical characteristics to LES-infected counterparts. 
This study was approved by the Local Research Ethics Committee (REC reference 
08/H1006/47). 
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Table 3.1. Patient details and phenotypic characteristic exhibited by sputum isolates from patients chronically infected with P. 
aeruginosa 
± 
 
 
Patient characteristics 
a
 Total 
 Mutations   
(%) 
Antibiotic resistance (%) Colony morphology type (%) 
 
 
 
Sex 
 
 
Age 
(y) 
 
 
FEV1 
(%) 
 
 
BMI 
 
 
n 
 
 
n
a
 
Sub 
HM Aux TOB COL CEF CIP MER TAZ GM GNMS Mtr 
MW
O 
StN
MS 
RM 
Non-
LES: 
      
              
CF20 M 26 41 23 80 22 25 95 61 0 75 42 20 17.5 2 48 0 2 48 0 
CF21 M 30 43 15 80 15 61 10 0 0 25 50 20 0 0 47 0 3 50 0 
CF22 M 21 38 16 80 8 0 100 0 0 2 5 0 0 2 76 0 0 22 0 
CF23 M 21 38 21 80 23 0 71 2 0 31 21 34 24 0 0 0 25 75 0 
CF24 M 22 54 20 80 16 22 0 0 0 61 90 46 0 0 76 0 24 0 0 
All 
(Mean) 
  
24 
 
43 
 
19 
400  
16.8 
 
22 
 
55 
 
13 
 
0 
 
39 
 
42 
 
24 
 
8 
 
1 
 
49 
 
0 
 
11 
 
39 
 
0 
LES: 
      
              
CF3 F 22 66 28 80 19 2 38 61 0 70 4 60 2 42 0 2 0 56 0 
CF4 M 33 45 19 80 31 8 12 12 0 10 16 2 2 4 36 0 34 24 2 
CF7 F 24 40 17 80 19 2 18 35 0 35 14 0 0 0 0 8 52 42 0 
CF8 F 27 39 18 80 16 5 52 8 0 55 12 94 48 72 14 0 12 0 2 
CF10 F 24 40 17 80 25 12 4 82 0 66 8 66 18 0 48 0 4 48 0 
ALL 
(Mean) 
  
26 
 
46 
 
20 
 
400 
 
21.6 
 
6 
 
25 
 
40 
 
0 
 
47 
 
11 
 
44 
 
14 
 
24 
 
20 
 
2 
 
20 
 
34 
 
1 
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Abbreviations: FEV1, Forced Expiratory Volume in 1 s; BMI, body mass index; HM, hypermutable phenotype; Aux, auxotrophy; 
TOB, tobramycin; COL, colistin; CEF, ceftazidime; CIP, ciprofloxacin; MER, meropenem; TAZ, tazobactam / pipericillin; GM, 
Green mucoid; GNMS, Green Non-mucoid smooth; Mtr, Mucoid transparent; MWO, Mucoid white opaque; RM, Red mucoid;   
SNMS, Straw coloured Non-mucoid smooth.                                                                        
 
a 
nSub indicates the total number of different sub-types for each set of 80 isolates. 
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3.2.2 Microbiology and phenotypic/genotypic tests 
Sputum samples were collected from adult CF patients at the Regional Adult Cystic Fibrosis 
Unit in Liverpool. These represented routine samples taken for diagnostic purposes, and 
clinicians determined the antimicrobial therapy. For each patient, two samples were taken: the 
first at the beginning of the exacerbation, before intravenous antibiotic treatment had 
commenced and the second at the end of the exacerbation when symptoms had resolved. 
Exacerbation was defined by a set criteria , including drop in FEV(forced expiratory volume in 1 
second), increased sputum or discoloration, temperature and increased cough (Goss & Burns, 
2007). All of the patients studied were chronically infected with the LES. Sputum was treated 
with an equal volume of Sputasol (Oxoid), incubated at room temperature with shaking at 200 
r.p.m. for 15 min, and then cultured on Pseudomonas selective agar with CN supplement 
(Oxoid). Forty single colonies were isolated per sputum sample, ensuring that each different 
colony morphology type was proportionately represented. Each of these 40 isolates was 
confirmed as P. aeruginosa LES using PCR tests for the amplification of the P. aeruginosa oprL 
gene (De Vos et al., 1997) and the two LES markers, PS21 (Parsons et al., 2002) and LESF9 
(Smart et al., 2006), before being subjected to a range of phenotypic tests.  
PCR amplification assays: PCR amplifications were carried out in a total volume of 25 ml. For 
each reaction, 1.25 U GoTaq polymerase (Promega), 16TaqMaster (Helena Biosciences), 300 
nM each oligonucleotide primer (Sigma-Genosys; Table  16 Taq buffer, 2.5mM  MgCl and 
100mM nucleotides (dATP, dCTP, dGTP, dTTP) was used along with 1 ml DNA from boiled 
suspensions of colonies. PCR amplification was carried out for 30 cycles of 95 uC (1 min), the 
chosen annealing temperature (2 min) and 72 uC (2 min). Following this, a final extension step 
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of 72 uC for 10 min was carried out. In the case of LES prophages 2, 3, 4 and LESGI-5, 
additional PCR assays were performed using primers designed for the flanking regions of the 
insertions, and therefore only if the insertion was not present would the expected band be 
observed. For PCR amplification to detect free phages directly from sputum samples, the sputum 
was first treated with Sputasol, diluted (1 : 10) with sterile distilled water, filter- sterilized (0.2 
mm) and DNase I treated as follows: addition of 3.5 U DNase I (Roche), 3.5 ml 106DNase I 
buffer and 3 ml sterile distilled water, followed by incubation for 15 min at room temperature. 
To stop the reaction 3.5 ml 25 mM EDTA (pH 8.0) was added and the solution was heated to 65 
uC for 10 min. Following this, PCR amplification was carried out using 5 ml of the phage 
preparation. Each PCR amplification reaction was replicated twice.   
Colony morphology: Colony morphology was assessed on Columbia agar plates (Oxoid), with 
each isolate assigned to one of six morphotypes: (1) green, non-mucoid and smooth (GNMS); (2) 
mucoid and transluscent (MTr); (3) mucoid and green (MG); (4) mucoid, white and opaque 
(MWO); (5) straw coloured, non-mucoid and smooth (StNMSm); (6) red/brown pigmentation 
and mucoid (RM).  
Antibiotic susceptibility: Using current BSAC guidelines (Andrews et al 2009) , antibiotic 
susceptibilities were determined by disk diffusion tests for six antibiotics that are commonly 
used to treat CF patients, namely: ceftazidime, colistin, ciprofloxacin, meropenem, 
tazobactam/piperacillin and tobramycin. The following amounts were used: 85 mg 
tazobactam/piperacillin, 10 mg meropenem, 10 mg tobramycin, 5 mg ciprofloxacin, 30 mg 
ceftazidime and 25 mg colistin sulphate (all from Oxoid). The sizes of the zones of inhibition 
(mm) were also recorded. Isolates were assigned as phenotype resistant or sensitive for all 
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antibiotics. For ciprofloxacin and meropenem an extra phenotype of intermediate resistance was 
included.  
Other phenotypic traits: Auxotrophy was determined by testing the ability of isolates to grow 
on glucose M9 media and hypermutability was assessed by determining spontaneous mutation 
rates on Luria agar containing rifampicin (Sigma) (300 μg / ml) following overnight growth in 
Luria broth (Oliver et al 2000).  
Each trait was assigned a number code (1-6 for morphology; 1 or 2 for all other tests with the 
exception of susceptibility to ciprofloxacin or meropenem [1-3]). A haplotype was defined as a 
specific combination of these trait values. For example, LES haplotype 1 has the code 1 for 
colony morphology, 2 for hypermutability, 2 for auxotrophy, 1 for susceptibility to tobramycin, 1 
for susceptibility to colistin, 3 for susceptibility to ceftazidime, 2 for susceptibility to 
ciprofloxacin, 3 for susceptibility to meropenem, 3 for susceptibility to tazobactam/piperacillin. 
From the numerical profiles generated, the relatedness of each isolate was calculated using the 
eBurst algorithm available at the site http://eburst.mlst.net.  
 
 
3.2.3 Statistical analyses 
In order to estimate the population differentiation between patients, between samples within 
patients and between isolates within samples, we performed hierarchical analysis of variance 
using the ade4 package in R (r-project.org). We define a sub-type as a specific combination of 
trait values, and the phenotypic distance between a pair of sub-types as the number of traits that 
differed between them. Sub-type diversity was calculated as the probability of two randomly 
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picked isolates being the same sub-type based on the sub-type frequencies within a sample. Sub-
type sharing between a pair of samples was calculated as the probability of a randomly picked 
isolate from each sample sharing the same sub-type. This sub-type sharing probability was 
normalised using a logit transform (log[p/(1-p)]). 
3.3 RESULTS 
3.3.1 Overall P. aeruginosa phenotypic diversity 
High phenotypic diversity was apparent in the P. aeruginosa populations from each of the 
chronically infected CF patients.  Based on the nine phenotypic traits analyzed, 400 isolates 
taken from 10 sputum samples from non-LES-infected patients comprised a total of 75 distinct 
phenotypic sub-types.  The number of sub-types present within each patient is shown in Table 
3.1, along with the frequency of each phenotypic characteristics measured.  When the data from 
LES-infected and non-LES-infected patients were analyzed together, there were 152 sub-types of 
P. aeruginosa present in total, of which 97 were found only in LES-infected patients, 76 were 
found only in non-LES-infected patients, and 21were shared between the two groups.  There was 
a mean of 10 sub-types per set of 40 isolates for samples from non-LES-infected patients, 
compared to 10 for samples from LES-infected patients. 
3.3.2 Sub-type variation in individual patients 
Hierarchical analysis of variance was performed on LES and non-LES groups separately to 
estimate the proportion of phenotypic variation attributable to (i) variation among patients, (ii) 
variation among samples within patients, and (iii) variation among isolates within samples.  In 
both groups, the greatest contribution to overall diversity was due to phenotypic diversity 
between isolates within samples (LES-infected patients, 83%; non-LES infected patients, 81%). 
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Overall, the LES and non-LES infections exhibited equivalent levels of diversity within a single 
sputum sample (Fig 3.1a) and an equivalent degree of correlation between different sputum 
samples taken from the same patient (Fig 3.1b) & (Fig 3S). 
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Figure 3. 1. Comparisons between non-LES and LES samples.  
(a) Diversity within LES and non-LES samples is calculated from the probability of two isolates within a sample 
being of the same sub-type (pshare). Circles and triangles represent samples from the beginning and end of an 
exacerbation, respectively. No statistically differences in diversity were observed, either between non-LES and LES 
samples or between samples from the beginning versus end of an exacerbation. 
(b) Similarity between pairs of samples taken from the same patient. Similarity is calculated from the probability of 
two isolates from different samples being of the same haplotype (pshare). Circles represent pairs of samples taken at 
the beginning and end of an exacerbation and, hence, less than one month apart. Triangles represent pairs of samples 
taken at the beginning of separate exacerbations more than two months apart. Dotted lines indicate the mean level of 
similarity between samples from different patients within either the non-LES or the LES groups 
3.3.3 Frequency of phenotypic traits 
Figure 3.1a 
Figure 3.1b 
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There were differences between the groups (samples from non-LES-infected patients and from 
LES-infected patients) with respect to some of the phenotypes tested.  There was a far greater 
range in prevalence of isolates exhibiting the hypermutability phenotype amongst the non-LES 
samples [Non-LES (0-61%, LES (2-12%)].  This was also observed for auxotrophy [Non –LES 
(0-100%), LES (4-52%)].    Susceptibilities to commonly used antibiotics varied considerably 
within patient samples, with the exception of colistin (no resistant isolates) (Table 3.1).    
3.4 DISCUSSION 
Within-host adaptation of P. aeruginosa during chronic CF infection results in the evolution of 
diversity within patients.  Previous studies, which have tended to focus on small numbers of 
sequential isolates (Smith et al 2006, Bragonzi et al 2009, Huse et al 2010), have concluded that 
P. aeruginosa adapts in specific ways, including loss of virulence. Yet, it has been demonstrated 
that concurrent pairs of isolates (taken from the same sputum sample) can also vary considerably 
from each other (Chung et al 2012), and we have shown previously that some strains of P. 
aeruginosa, such as the LES, exhibit dynamic turnover of sub-types exhibiting different 
phenotypic and genotypic characteristics (Mowat et al 2011).  It has been suggested that some 
strains reach an evolutionary plateau, characterized by low phenotypic variations (Cramer et al 
2011), leading us to wonder whether the extensive diversification seen with chronic LES 
infections may be a particular feature of this epidemic strain.  In this study we analyzed samples 
from multiple adult CF patients infected with non-LES P. aeruginosa strains and compared them 
with equivalent samples from LES-infected patients.  Our observations of diversity in sub-type 
composition within single sputum samples from both the LES and the non-LES-infected patients 
suggest that the extensive diversity reported previously is a widespread feature of P. aeruginosa 
populations in the lungs of CF patients who have been chronically infected for long periods. For 
both groups (LES and non-LES), the greatest contribution to the diversity in sub-types observed 
was within individual sputum samples, rather than because of variation between patients, even 
though the non-LES group patients were each infected with a different strain. 
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The wider range of frequencies of some of the phenotypic traits measured between the LES-
infected and the non-LES-infected groups is likely to be due to strain-specific variations in the 
non-LES group.  Hence, although the extent of diversity was not different between the two 
groups, the actual phenotypes contributing to the variations did differ.  For example, it was 
notable that isolates with the HM phenotype were present amongst the sets of 40 isolates 
analyzed in all of the samples from patients infected with the LES, but this was not the case for 
samples containing non-LES strains.  However, there was no clear link between detectable HM 
phenotype and the number of subtypes identified in a patient.  For example, although no HM 
isolates were identified amongst isolates tested from patient CF23, the P. aeruginosa population 
exhibited the highest number of different sub-types amongst the 80 isolates tested for each of the 
non-LES group. 
Hence, this study provides further evidence that the CF lung, which constitutes a spatially 
heterogeneous environment with multiple discrete ecological niches, is able to sustain multiple 
divergent sub-types of P. aeruginosa simultaneously, and that this is a common feature of these 
kinds of infections. 
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Fig 3.S1: Haplotype variation seen in LES and Non –LES patients. (As demonstrated by e-burst) 
 
 
 
Pink – both LES and non-LES
Green – LES only
Black – non-LES only
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4.1 Abstract:  
 
Background: Transmissible Pseudomonas aeruginosa (Psa) strains such as  Liverpool 
Epidemic Strain (LES) are now widespread throughout UK CF clinics: its 
susceptibility to antibiotics is therefore important. To study this, we compared 
antibiogram patterns of Psa strains in our CF clinic over 5 years, looking at 
differences in resistance patterns between strains and changes to these over time.  
 
Methods: The antibiograms of sputum samples collected at annual review between 
2004 and 2008 from patients attending our centre were included. We compared Psa 
isolate antibiotic resistance (to six anti-pseudomonal antibiotics) patterns for patients 
infected with LES with those infected with other Psa strains, both in the total 
population in 2004 (125 patients) and 2008 (202 patients) and also longitudinally 
from 2004 to 2008 in matched and unmatched patients.   
 
Results: LES exhibited significantly more resistant isolates in 2004 (p<0.0001). There 
was an increase in antibiotic resistance in both LES and other Psa strains over time 
(p<0.001). Cox proportional hazards analysis of both unmatched (n=125) and 
matched (n=56) patients in 2004 revealed that LES infected patients were more likely 
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to develop antibiotic resistant isolates over time (hazard ratio 8.1, p<0.001). Fewer 
LES isolates were classed as fully sensitive in both matched and unmatched groups at 
the end of study period (p<0.001). 
 
Conclusion: This study shows a worrying trend in antibiotic resistance in the Psa 
isolates amongst those chronically infected with LES. This highlights the need to 
prevent cross infection through segregation and also the need to develop new 
strategies to treat these organisms. 
 
 
4.2 Background:  
Chronic respiratory infection with Pseudomonas aeruginosa (Psa) is the major cause 
of morbidity and mortality in CF (1797 Kerem 1990; 1831 Henry 1992), where most 
deaths are due to end stage lung disease (Zuckerman et al 1998). Treatment of these 
infections involves combinations of intravenous anti-Psa antibiotics, often given over 
prolonged periods, which may encourage antibiotic resistance (Cheng et al 1996, Pitt 
et al 2003) and also enhance toxicity (Katbamna et al 1998, Green et al 1985). 
Furthermore, the recent emergence of Psa clones that are highly transmissible 
between CF individuals and have been shown to confer a worse prognosis (Al- aloul 
et al 2004, Griffiths et al 2005, Bradbury et al 2008) has complicated antimicrobial 
management. 
Despite this, there have been no systematic studies looking at antibiotic resistance 
over time in Psa in the CF community. We therefore undertook a 5 year prospective 
study of the antibiotic resistance of Psa in patients attending a large adult CF unit in 
the north-west of England, where there is a cohort of individuals chronically infected 
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with the Liverpool Epidemic Strain (LES) of Psa, the most prevalent and important 
such transmissible strain in the UK (Scott & Pitt 2004). We looked for any differences 
in resistance patterns between strains and whether these patterns have changed over 
time.  
 
4.3 Patients and Methods:  
 
4.3.1 Patient cohorts 
The Liverpool Adult CF Unit provides specialist services for North Wales, Cheshire, 
Merseyside, and the Isle of Man: a catchment of approximately 3 million people. All 
adult CF patients have regular (at least bimonthly) sputum analysis for Psa and to 
prevent cross-infection we have regularly genotyped their strains for many years.  
Patients who were chronically infected with Psa (defined by at least 3 positive sputum 
samples within a 6 month period) (Fredericksen et al) formed the study population. 
For the purposes of this study, patients additionally chronically infected with 
Burkholderia cepacia complex and the only 2 with another known transmissible Psa 
strain (Midlands1) were excluded.  
We looked at Psa isolates cultured from samples between 2004 and 2008: to 
standardise antibiogram selection, the results from the sputum sample closest to the 
anniversary of the patient’s birthday were used for each year for all patients. 
We compared Psa isolate antibiotic resistance patterns for patients infected with LES 
with those infected with sporadic Psa strains, both in the total population in 2004 (125 
patients) and 2008 (202 patients) and also longitudinally from 2004 to 2008 in both 
matched and unmatched patient groups (see below).  
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4.3.2 Patient matching and statistical analysis 
We used a propensity score (Black et al 2002) for LES group membership in order to 
allow matching with the other group. This was determined without regard to outcome, 
using multivariable logistic regression analysis with a full non-parsimonious model 
that included all available patient characteristics, balancing all items recorded that 
may relate to either systematic bias or simple chance. This model yielded a C statistic 
of 0.78, indicating an acceptable ability to differentiate between patients with or 
without LES. We then used a macro (www2.sas.com/proceedings/sugi29/165-
29.pdf) to perform propensity matching. Using this model, in 2004 28 LES infected 
patients were matched with 28 infected with other Psa strains on clinical parameters 
(age, sex, FEV1, BMI, time since diagnosis of CF, hospital admissions, outpatient 
visits and baseline antibiotic resistance) (Table 4.1). 2004 patient demographics are 
shown in Table 4.1. 
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Table 4.1: Characteristics of 125 adult CF patients chronically infected with P. 
aeruginosa attending the Liverpool Adult CF Centre in 2004 (unmatched and 
matched groups 
 
 
Categorical variables shown as percentage, comparisons made with 2 test; 
 
Continuous variables shown as median (25
th
 - 75
th
 percentiles), comparisons 
made with Wilcoxon rank sum  
  
 
Unmatched Matched (n=56) 
Other Psa 
Infection 
(n=34) 
LES Psa 
Infection 
(n=91) 
p value 
Other Psa 
Infection 
(n=28) 
LES Psa 
Infection 
(n=28) 
p value 
 
Female (%) 43 53 0.44 46 43 0.79 
Years since 
diagnosis 
22 (16-27) 25 (23-29) 0.003 23 (18-29) 23 (21-26) 0.62 
Age (years) 26 (21-34) 29 (24-36) <0.01 25 (23–34) 27 (25-32) 0.18 
BMI 22 (20-24) 21 (19-23) 0.08 21 (20-24) 22 (19-25) 0.80 
FEV1 (%) 64 (46-83) 64 (45-85) 0.88 63 (45~88) 77 (49-94) 0.45 
Hospital 
admissions 
4 (1-7) 8 (4-14) <0.001 4 (1-7) 6 (3-10) 0.45 
Outpatients 
visits 
33 (21-38) 36 (22-50) 0.29 33 (21-36) 31 (17-49) 0.89 
Baseline 
antibiotic 
resistance 
(%) 
11.4 46.2 <0.001 14.3 10.7 >0.99 
  
84 
Cox proportional hazards analysis was then used to determine changes in antibiotic 
resistance over time in both the matched and unmatched groups. 
Statistical significance was calculated using Fisher’s exact test and Chi squared tests 
with Yates correction: p<0.05 was considered to be significant. Stata software version 
2.0 was used to analyse the data. 
 
4.3.3 Microbiological methods  
 
Antibiotic susceptibility testing: 
Sputum samples were treated with equal quantities of sputasol (oxoid), agitated at 200 rpm 
for 15 minutes at room temperature, plated onto blood & chocolate agar and MacConkey 
agar, and incubated at 37˚ C. The plates were examined at 48 hours for growth of Psa 
colonies, and those with distinct morphotypes were further cultured onto purity plates 
(chocolate agar). Each morphologically different subtype (up to 5 per sample) was tested 
for antibiotic susceptibility using BASC guidelines (Andrews et al 2009) by the disc 
diffusion method using the following: tazobactam/piperacillin 85 µg, meropenem 10 µg, 
tobramycin10 µg, ciprofloxacin 5 µg, ceftazidime 30 µg and colistin sulphate 25 µg. The 
sizes of the zones of inhibition (mm) were recorded and susceptibilities were defined as per 
standard protocols. In total 9200 susceptibility patterns were analysed.  
Sputum samples with multiple morphotypes were judged to be sensitive only if all 
morphotypes were sensitive to at least two of the three class of antibiotics tested 
(fluoroquinolones, aminoglycosides, and beta-lactams/carbapenems). Strains were defined 
as resistant if they were resistant to two of the three classes of antibiotics  (CF Foundation 
2004) and pan-resistant if resistant to all three classes of antibiotics. 
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4.3.4 Psa genotyping: 
Oligonucleotide primers (Sigma-Genosys) used in PCR assays were (PASS, PS21R, 
PS21F, LESF9F, LESF9R). DNA for PCR amplification was prepared by making a 
suspension of a few colonies in 200 ml 5% Chelex-100 (Sigma) solution. After 
vigorous mixing, the suspension was boiled for 5–10 min. Following centrifugation, 
150 ml of supernatant containing the DNA was removed and stored at -22°C. 
Typically, 1 ml of this DNA was used directly in 25 ml volumes containing 1.25 units 
Taq DNA polymerase (Promega), 16 TaqMaster (Helena Biosciences), 300 nM each 
primer, 16 Taq buffer, 2?5 mM MgCl2 and 100 mM nucleotides (dATP, dCTP, 
dGTP, dTTP). Amplifications were carried out in an Eppendorf MasterCycler thermal 
cycler for 30 cycles consisting of 95 uC (1 min), annealing temperature (1 min) and 
72 uC (2 min), with an additional extension time at 72 uC (10 min) following 
completion of the 30 cycles. 
Psa and LES strains were identified using gel electrophoresis looking for bands 
representing specific amplicons (Panagea et al 2003, Panagea et al 2005). The PA-SS, 
primer pair, specific for all Psa, yields an amplicon of 956 bp; the LES-specific 
primer pairs LESF9 and PS21 yield amplicons of 461 bp and 364 bp respectively. 
PCR tests leading to the PA-SS amplicon only were deemed LES-negative. Tests 
leading to the presence of all three amplicons (PA-SS, LESF9 and PS21) were 
deemed LES-positive (Smart et al 2006, Fothergill et al 2008). 
 
4.4 Results: 
4.4.1 Cross-Sectional (Unmatched) Analysis of 2004 and 2008 cohorts 
Analysis of the 2004 antibiograms showed that LES was more resistant to 
ceftazidime, meropenem, piperacillin/tazobactam (all p<0.001) and tobramycin 
(p=0.0001) than other Psa strains, which in turn were more resistant to ciprofloxacin 
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(p<0.002) (Table 4.2). There was no resistance to colomycin in either group. Overall, 
pooled resistance was greater in the LES group (mean 18.1%) than the other Psa 
group (mean 7.2%), (p<0.0001).  
Analysis of the 2008 antibiograms showed that, compared to 2004, the overall mean 
antibiotic resistance increased in both groups, but LES isolates became significantly 
more resistant (p<0.0001) to all antibiotics except colomycin when compared to other 
Psa isolates (Table 4.2). Although in 2008 the other Psa isolates showed increased 
mean resistance to ciprofloxacin (10.6% vs 20.6%, P=0.0002), tobramycin (3.5 vs 8.5, 
p=0.002) and colomycin (0 vs. 2.8, P=0.008), the LES isolates had increased mean 
resistance to all six antibiotics used (all P<0.0001 except piperacillin/tazobactam 
p=0.01). The proportions of resistant and pan-resistant strains were also significantly 
higher in the LES group (see fig 4.1). 
Table 4.2 & fig 4.1 
 
  
87 
Table 4.2: Mean antibiotic resistance exhibited by LES Psa and Other Psa isolates to six commonly used antibiotics in 2004 & 2008 
 
 n = number of isolates 
 
 2004 2008 
Change in antibiotic 
resistance within Psa 
type 
Antibiotics 
Other Psa 
%resistant 
(n=303) 
LES Psa 
%resistant 
(n=685) 
p-value 
Other Psa 
%resistant 
(n=580) 
LES Psa 
%resistant 
(n=1196) 
 
p-value 
Other Psa 
2004 v 
2008 
p-value 
LES Psa 
2004 v 
2008 
p-value 
Ciprofloxacin 10.6 5.1 0.002 20.7 34.4 <0.0001 0.0002 <0.0001 
Ceftazidime 9.3 39.3 <0.0001 12.9 58.1 <0.0001 NS <0.0001 
Tobramycin 3.0 10.5 0.0001 8.5 35.1 <0.0001 0.002 <0.0001 
Colomycin 0.0 0.0 NS 2.8 3.6 NS 0.008 <0.0001 
Piperacillin/Tazobactam 10.9 26.3 <0.0001 10.9 31.5 <0.0001 NS 0.01 
Meropenem 9.6 32.0 <0.0001 11.7 43.1 <0.0001 NS <0.0001 
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4.4.2 Longitudinal follow up of 2004 cohort:  
Unmatched cohort: 
The 125 patients in the 2004 cohort were followed for up to 5 years. Compared to the 
other Psa infected group, in terms of baseline demographics the 91 patients 
chronically infected with LES had a significantly higher age, mean antibiotic 
resistance, time since diagnosis, and number of hospital admissions, but no difference 
in sex, FEV1, BMI or number of outpatient visits than those with unique strains (see 
Table 4.1). Although Cox proportional hazards analysis revealed that the LES infected 
patients were more likely to develop antibiotic resistant isolates over time (hazard 
ratio 8.1, p<0.001) (table 4.3), as were female CF patients (hazard ratio 1.56, 
p=0.045) and those with a lower baseline FEV1 (hazard ratio 0.99, p=0.03), BMI and 
time since the diagnosis of CF had no effect. At the end of the 5 year study period, 
there were 15 deaths and 3 transfers in patients with LES compared to 4 deaths and 1 
transfer in those with other Psa, and fewer LES group patient isolates were classed as 
sensitive (9/73), compared to 25/31 in the other Psa group (p<0.001) (see fig 4.1). 
Matched cohort: 
Cox proportional hazards analysis of the 56 matched patients showed that LES 
infection (hazard ratio 6.1, p<0.001) and lower baseline FEV1 (hazard ratio 0.98, 
p=0.03) increased the likelihood of developing antibiotic resistant isolates over time, 
whilst female sex, BMI or time since diagnosis had no effect (table 3). Even when 
adjusted for those clinical variables predicting antibiotic resistance over time (age, 
sex, BMI, FEV1, number of hospital admissions), LES infected patients developed 
more antibiotic resistant isolates during the 5-year period (fig 4.2) (isolates classed as 
sensitive: LES infected group [21.7%] versus other Psa infected group 22 [88.5%], 
p<0.001). 
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Table 4.3: Cox proportional hazards for follow up antibiotic resistance in 
unmatched & matched cohorts 
Variable Hazard ratio 
95% confidence 
interval 
p-value 
Unmatched population (n=125)    
LES 8.1 3.79 to 17.39 <0.001 
Female 1.56 1.01 to 2.40 0.046 
2004 BMI 1.00 0.93 to 1.07 0.99 
2004 FEV1 % 0.99 0.98 to 1.00 0.03 
Time since diagnosis 1.00 0.97 to 1.00 0.82 
    
Matched population (n=56)    
LES 6.1 2.48 to 15.18 <0.001 
Female 1.34 0.63 to 2.87 0.44 
2004 BMI 1.12 0.98 to 1.27 0.09 
2004 FEV1 % 0.98 0.96 to 1.00 0.03 
Time since diagnosis 1.00 0.96 to 1.05 0.76 
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Fig 4.2: Antibiotic sensitivity profile of patients chronically infected with LES and other Psa strains attending Liverpool Adult CF Unit 
between 2004-2008.*   
 
* Antibiotic sensitivity adjusted for number of patients in each group/ year 
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4.5 Discussion: 
For the first time to our knowledge we report a longitudinal analysis of the antibiotic 
sensitivity patterns of Psa strains in chronically infected adult CF patients, including 
those of the most common transmissible Psa strain in the UK, LES. Our results 
demonstrate a high prevalence of antibiotic resistance in Psa isolates in patients 
infected with LES and an increased rate of acquisition of antibiotic resistance over 
time, compared to unique Psa strains.  
Morbidity in patients with CF results from chronic suppurative lung disease due to 
Psa, where repeated exacerbations cause progressive lung damage leading to 
respiratory failure and death in the majority of cases (Zuckerman et al 2007, Belkin et 
al 2006).  Up to 70% of adult CF patients in the UK are chronically infected with Psa 
strains (UK CF registry 2008). Possibly due to selective antibiotic pressures, over 
time these organisms undergo genotypic changes leading to the emergence of 
treatment-resistant phenotypes: it was the appearance of such a ceftazidime-resistant 
phenotype at out local paediatric CF centre that led to the important discovery of the 
original transmissible clone of Psa, LES, in 1996(Cheng et al 1996). LES is 
widespread throughout UK CF units (Scott &Pitt 2004) and has also been discovered 
elsewhere in the World (Aaron et al 2008): it causes increased morbidity, confers an 
increased healthcare burden, hastens clinical deterioration (Al-Aloul et al 2004, 
Ashish et al 2010) and can even spread to non-CF patients (McCallum et al 2002) and 
across species (Mohan et al 2008). Other transmissible strains have since been 
discovered (Griffiths et al 2005, Armstrong et al 2003, Brimicombe et al 2008, Fluge 
et al 2001, Dinesh et al 2003, Ojeniyi et al 2000, Jones et al 2005, Speert et al 2002, 
O'Carroll et al 2004, Tubbs et al 2001), and whilst some these have shown increased 
virulence and antibiotic resistance and can cause poorer clinical outcomes (Al-Aloul 
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2004, Griffiths et al 2005, Jones et al 2001), these traits are not universal (Speert et al 
2002, O'Carroll et al 2004, Tubbs et al 2001). 
Although a number of workers have shown the presence of resistant isolates of 
transmissible strains in their patients (Al-Aloul et al 2004, Griffiths et al 2005, Jones 
et al 2001, Denton et al 2002) none have demonstrated the presence of an excess of 
multiresistant strains, and there have been no previous studies looking at how the 
antibiotic sensitivity patterns of these epidemic strains may change over time. We 
have a large cohort of LES-infected CF patients, mainly inherited from paediatric 
practice, and this has given us the opportunity to study this strain over a prolonged 
period.  
From our longitudinal study of up to 200 adult patients over 5 years, we have 
demonstrated that LES is not only more resistant to antibiotics, but also has an 
enhanced rate of acquisition of antibiotic resistance over time. We have previously 
shown that chronic infection with LES causes increased hospitalisation and IV 
antibiotic use (Al-Aloul et al 2004).  However, this increased antibiotic resistance 
may not simply be a reflection of repeated antibiotic exposure leading to the 
emergence of resistance by natural selection, since the effect was still seen following 
adjustment for confounding factors, and antibiotic pressure only had a weak effect.  
The ability of Psa to mutate rapidly (hypermutate) in the harsh environment of the CF 
lung that may give it a survival advantage (Mena et al 2008, Oliver et al 2000), has 
also been suggested as an explanation for the emergence of antibiotic resistance. 
However, although hypermutable Psa strains can occur in up to 36% of CF patients 
(Oliver et al 2000) we have found that hypermutability occurs less frequently amongst 
LES isolates (Fothergill et al 2007) suggesting an alternative explanation for its 
resistance to antibiotics is required. 
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Many isolates of LES, including those associated with transmission to non-CF 
patients, exhibit an unusual quorum sensing (QS) phenotype termed hypervirulence 
(Winstanley et al 2009). This phenotype is characterized by a dysfunctional QS 
system, leading to overproduction of QS-regulated factors too early in the growth 
phase. These hypervirulent isolates produce high levels of pyocyanin and other QS-
regulated exoproducts of relevance to CF infections (Fothergill et al 2007), and also 
exhibit greater killing activity against Drosophila and C. elegans (Salunkhe et al 
2005). The phenotype has also been linked to increased resistance to some antibiotics 
(Fothergill et al 2007) and has not been identified in other Psa isolates, whether in CF 
or other hosts. Hence, it seems feasible that it might play a role in the success of this 
epidemic clone, the greater morbidity associated with it, and the development of 
resistance.  
LES has also been found to possess an unstable genotype: the subtypes within LES 
undergo deletions, insertions and rearrangement leading to significant phenotypic 
changes (Fowerekar et al 2009, Fothergill et al 2010). In a UK based survey looking 
at several transmissible strains, LES had greater microheterogeneity than other strains 
underlining its genetic variability. 
There are limitations to our study. Firstly, we applied in vitro antimicrobial sensitivity 
testing to organisms existing in the special circumstances of the CF lung, where Psa 
lives in a complex anaerobic bio-film community (Hill et al 2005), and exhibits 
extensive phenotypic divergence, including a mucoid form. Removing these 
organisms and growing them in planktonic media in aerobic conditions may not 
mirror sufficiently their natural habitat. Furthermore, many different subtypes may 
exist within the same sputum sample, each with a different antibiogram (Fowerekar et 
al 2009; Fothergill et al 2010). Nevertheless, we standardised our approach to the 
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assessment of antibiotic resistance by collecting samples at the same fixed time points 
for each patient, and utilising industry standard methodology (Andrews et al 2009) 
towards antimicrobial testing. Furthermore, by using the same technique for all Psa 
isolates (both LES and other strains) over a prolonged period the results produced are 
comparable. Even though individual sputum sensitivities may not be representative of 
the true sensitivity in an infecting bacterial population, using longitudinal data over 5 
years gives us a glimpse of the overall trends of the antibiotic resistance patterns in 
these patients, confirming the developing problem of antibiotic resistance in 
transmissible Psa in CF patients, particularly in those with LES infection. Secondly, 
we only studied LES and not other transmissible strains, so we cannot be sure that our 
conclusions are valid for all such strains. However, LES is the most prevalent 
transmissible strain in the UK and has already spread to units elsewhere, so our 
findings will be of relevance to all CF units.  
In conclusion, this study shows a worrying trend in antibiotic resistance in Psa isolates 
in the CF population, particularly amongst those chronically infected with LES, which 
not only exhibits more antibiotic resistance but also develops resistance much more 
rapidly than other Psa strains. This highlights the requirement for new antimicrobial 
therapies and the paramount need to enforce stringent infection control and 
segregation policies in CF units to limit the spread of transmissible Psa strains to 
improve outcomes for CF patients.  
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Chapter 5: The increased healthcare economic burden associated with chronic 
infection with transmissible Pseudomonas aeruginosa strains in CF. 
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5.1 Abstract: 
Background: Although chronic infection with transmissible Pseudomonas aeruginosa 
(Psa) strains causes increased treatment requirements, morbidity, and ultimately 
mortality in CF patients, the burden this places on the healthcare economy, of 
increasing importance in these times of financial austerity, has not been studied.  
 
Methods: To investigate this further, using logistic regression we matched (for age, 
sex, BMI, FEV1, and diabetes) 40 adult CF patients chronically infected with the 
commonest UK transmissible Psa strain (the Liverpool Epidemic Strain, LES) with 40 
infected with unique Psa strains and compared their healthcare costs (inpatient and 
outpatient care, antibiotic therapy, and regular prescriptions) over a 4 year period. 
Statistical significance was calculated using the chi-squared test with Yates correction 
and Wilcoxon sign rank test for non-parametric data 
 
Results: The mean cost per patient per year was higher for LES patients for inpatient 
care (£4393.37 v £1817, p=0.0006), outpatient attendance (£3764 v £2515.91, 
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p=0.0035) and also hospital antibiotic therapy (£980 v £ 505, p=0.001). Regular 
prescription costs were similar in both groups. Overall, the healthcare cost of caring 
for an adult CF patient with LES chronic infection was significantly more (1.6 times) 
than that for a matched patient with unique Psa strain chronic infection.  
 
Conclusions: CF patients chronically infected with LES place an additional burden on 
the healthcare economy than that associated with chronic Psa infection. This has 
implications for the financial modelling currently underway in the UK to adequately 
resource CF units, and also underlines the need to prevent infection with transmissible 
Psa strains by effective cross infection control strategies.   
 
5.2 Background:  
Cystic fibrosis is the commonest potentially fatal inherited disease in the Western 
World, where a faulty gene interferes with salt and water transport in mucus 
producing cells, resulting in abnormally thick mucus, which causes organ damage and 
eventual failure. Although improvement in the diagnosis and treatment of patients 
with CF over the last two decades has resulted in better outcomes, the average life 
expectancy is still only 39 years (UK CF Registry 2008). 
 
This improvement in life expectancy is the direct result of various cost-intensive 
advances including the provision of expensive mucus thinning drugs and antibiotics, 
and the development of specialist centre care through dedicated multidisciplinary 
teams. However, chronic lung infection particularly due to organisms such as 
Pseudomonas aeruginosa (Psa) remains the major cause of morbidity and mortality in 
CF patients (Kerem et al 1990, Henry et al 1992) with the majority of deaths due to 
end stage lung disease. As patients with the disease live longer, new challenges to 
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both patients and clinicians have emerged, including cross infection with strains of 
Psa, which can spread between patients (Zuckerman et al 1998). The first reported 
such strain (the Liverpool Epidemic Strain, LES) can cause a rapid decline in clinical 
prognostic markers such as lung function and nutritional state, and increases the need 
for antibiotic therapy and hospital admission. (Cheng et al 1996, Al-Aloul et al 2004)  
Once acquired, it cannot be eradicated and can not only super-infect and replace 
existing Psa strains in CF patients but is also capable of infecting non-CF individuals 
(McCallum et al 2002, McCallum et al 2001) and crossing species (Mohan et al 
2008). A UK based survey of CF centres demonstrated LES to be the most common 
strain, present in 11% of CF clinics and accounting for 48% of all epidemic strains 
(Scott  & Pitt 2004): it has now also been reported in Canada (Aaron et al 2008) 
However, despite an increasing body of evidence establishing the ill effects of these 
epidemic strains in the UK and worldwide, there have been no systematic studies 
looking at the cost implications, healthcare resource utilisation or disease burden 
associated with their presence. Such an economic evaluation would require the 
analysis of both the costs and outcomes of two or more competing uses of healthcare 
resources in order to generate an overall comparative assessment.   
In our Specialist Adult CF Centre in the North-West of England, a post hoc analysis 
of our clinic population in 2000 revealed that 79% of those chronically infected with 
Psa harboured LES (Salunkhe et al 2005). We therefore undertook a 4-year study of 
the healthcare resource costs of our CF patients infected with LES, and compared 
them with to those infected with sporadic Psa strains.  
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5.3 Methods:   
We prospectively collected data on treatment burden, complications and the total 
costs involved for patients infected with LES and those infected with sporadic Psa 
strains, longitudinally for the 4 year period 2005-2008 in matched patient groups 
(Table 5.1). Data regarding hospital spells, outpatient visits, radiology and blood tests 
were collected from the hospital database. Details of medication use were collected 
from medical and nursing notes, and the pharmacy database. Unit costs were 
determined from Department of Health national tariffs and drug costs from the 
pharmacy procurement files. Nursing and physiotherapy time required by patients 
each day were estimated from the experience of senior nursing and physiotherapy 
staff. 
 
Patient demographics (matched and unmatched groups) are shown in Table 1 
Table 5.1: Unmatched patient characteristics 
 
 LES Negative 
(n=42) 
LES Positive 
(n=121) 
p-value 
Female 45.2 48.8 0.69 
Diabetes 35.7 58.7 0.01 
Age (years) 28.3  (23.9 – 29.1) 26.9  (24.4 – 32.1) 0.48 
FEV1 69  (47 – 84) 53  (37 – 77) 0.046 
BMI 23  (20 – 26) 21  (18.9 – 23.3) 0.006 
Mortality 7.1 9.9 0.76 
 
Categorical variables shown as percentage, comparisons made with 2 test; 
Continuous variables shown as median (25
th–75th centiles), comparisons made with 
Wilcoxon rank sum test 
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Chronic infection with Psa was defined as its isolation in 3 or more consecutive 
sputum samples in a 12-month period. All patients with LES had acquired it prior to 
transfer from the paediatric sector, and a strict inpatient and outpatient segregation 
policy is in place to prevent cross infection. We have been carrying out genotypic 
identification of Psa strains in respiratory samples from all patients attending our 
service since December 2003, where LES and other epidemic Psa strains are 
identified using combined multiplex PCR (Smart et al 2006).  Respiratory samples 
from patients known to be colonised with LES undergo an annual genotypic 
confirmation, whilst those from the remaining PSA infected patients undergo 3 
monthly genotyping to look for the main UK epidemic strains (LES, Midland1 and 
Manchester strains). We therefore know the Psa genotypes of all our patients at all 
times.  
The quality of life of patients with epidemic Psa strains in comparison to unique Psa 
strains has been addressed elsewhere. (Ashish et al 2010) We will however draw upon 
the overall conclusions in order to evaluate the relationships between QoL and costs. 
 
5.3.1 Patient matching and statistical analysis:  
To enable comparisons to be made between patients without the influence of 
underlying variations in characteristics and health state we developed a propensity 
score (Blackstone et al 2002) for LES group membership, which allowed matching 
with other groups. This was determined without regard to outcome, using a 
multivariable logistic regression analysis with a full non-parsimonious model that 
included all available patient characteristics, balancing all items recorded that may 
relate to either systematic bias or simple chance. This model yielded a C statistic of 
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0.78, indicating an acceptable ability to differentiate between patients with or without 
LES. We then used a macro (www2.sas.com/proceedings/sugi29/165-29.pdf) 
to perform propensity-matching. Using this model, in 2005, 40 LES infected patients 
were matched with 40 infected with other Psa strains on clinical parameters (age, sex, 
FEV1, BMI and diabetes (Table 5.2). We used mean values to compare costs between 
the different groups.  
Table 5.2: Matched patient characteristics 
 LES Negative 
(n=40) 
LES Positive 
(n=40) 
p-value 
Female 45.0 42.5 0.82 
Diabetes 37.5 35.0 0.82 
Age (years) 27.8  (23.9 – 38.8) 30.4  (25.0 – 34.7) 0.44 
FEV1 69  (47 – 83.5) 68  (49.5 – 88) 0.83 
BMI 22.5  (20 – 26) 22.5  (20.0 – 25.4) 0.81 
Mortality 7.5 7.5 >0.99 
 
Categorical variables shown as percentage, comparisons made with 2 test; 
Continuous variables shown as median (25
th–75th centiles), comparisons made with 
Wilcoxon rank sum test 
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Statistical significance was calculated using the chi-squared test with Yates correction 
and Wilcoxon sign rank test for non-parametric data. p<0.01 was considered to be 
significant. Stata software version 2.0 was used to analyse the data. 
 
5.4 Results:   
Of the 163 patients in 2005, 121 were chronically infected with LES (74.2%). 
Univariate analysis of the 2005 cohort revealed that patients with LES had a 
significantly lower FEV1, BMI and a higher prevalence of diabetes (table 5.1). The 
well-matched patient groups were followed up to analyse disease burden, overall costs 
and healthcare resource utilisation (table 5.3-5.4) continuous variables shown as 
median (25
th–75th centiles), comparisons made with Wilcoxon rank sum test. 
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Table 5.3: Matched cohorts; disease burden 
 LES Negative 
(n=40) 
LES Positive 
(n=40) 
p-value 
Hospital care    
Inpatient days 15.2  (5.2 – 32) 60.2  (31.7 – 99.2) <0.001 
Inpatient admissions 2  (1 – 5) 6.8  (4 – 11.2) <0.001 
Nursing time 98.8  (33.8 – 208) 391.0  (205.9 – 644.8) <0.001 
Physiotherapy time 5.7  (2 – 12) 22.6  (11.9 – 37.2) <0.001 
Outpatient visits 4.7  (3.8 -7.0) 7  (4.6 – 8.2)        0.01 
    
Home IV 52.5 55 0.82 
    Mean number/year 11.2  (0 – 44.8) 14  (0 – 56) 0.58 
 
Port 12.5 32.5 0.03 
Assisted feed PEG 0 5.0 0.49 
Deranged liver enzymes 32.5 32.5 >0.99 
Depression 2.5 12.5 0.20 
    
Repeat prescriptions    
Oral energy drinks 32.5 47.5 0.17 
Macrolide 65 67.5 0.81 
    Median duration 15.5  (0 – 35) 22  (0 – 35.5) 0.91 
Oral Steroids 12.5 30 0.056 
   Median oral antibiotics / year 1 (0.8 – 1.4) 1 (0.8 – 1.9) 0.36 
Inhaled antibiotics 67.5 62.5 0.64 
   Median duration 16  (0 – 32.75) 21.5  (0 – 48) 0.60 
DNAse 37.5 50 0.26 
   Median duration 
 
12.2  (0 – 28.5) 14.6(0- 48) 0.49 
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Tests     
Mean radiology tests / year 1 (0.8 – 1.5) 1.5 (1 – 2.4) 0.05 
Mean blood tests / year 5 (3.6 – 6) 7.1 (5.9 – 10.5) <0.001 
Mean microbiology tests / year 4 (2.5 – 6.1) 4.5 (3.6 – 5.6) 0.65 
    
 
Categorical variables shown as percentage, comparisons made with 2 test  
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Table 5.4: Matched cohorts, patient costs 
her Strains COST LES COST 
Cost variable 
Mean 
cost 
95% 
confidence 
Mean 
cost 95% confidence  p value 
Inpatient cost                     1817 (807.2 - 2827). 4393.37 (3383- 5403) p=0006 
Nursing cost 550 (244.6 - 856.5) 1331 (1025- 1637) p=0006 
Physiotherapy cost 116 (51.31 -179.7) 279 (215.0- 343.4) p=0006 
Outpatient cost 2515.91 (1933. - 3099) 3764 (3181 -4347) p=0035 
Cost of macrolide  (azithromycin) 339 (235.8 - 441.9) 353 (249.8 - 455.8) p=0.85 
Cost of inhaled antibiotic 1042 (425.6 - 1658) 1119 (502.6 - 1735) p=0.86 
Cost of DNAse 1780 (950.5 -2609) 2121 (1302 - 2941) p=0.56 
Cost of oral abx 80.5 (51.91 - 109.0) 85.5 (56.94 -114.0) p=0.81 
Cost of home iv 225.5 (102.9 - 348.5) 295.24 (172.5 - 418.0) p=0.43 
Cost of iv hospital abx 505 (363.8 - 647.1) 980 (842.2- 1118) p=0.001 
Cost of blood tests 8.15 (6.8 -9.4)   10 (8.759 - 11.28) p=0.03 
Cost of microbiology 31.65 (25.30 - 37.97) 32.6 (25.40 - 39.80) p=0.84 
Cost of TIVAD 51.31 (6.526 - 96.11) 105.62 (61.97- 149.3) p=0.08 
Cost of radiology 12 (3.069 - 21.02) 24.5 (15.49 -33.44) p=0.05 
Mean cost /yr 9074.02 14893.83 
  
p=0.001 
 
 Categorical variables shown as percentage, comparisons made with 2 test; 
Continuous variables shown as mean (25
th–75th centiles), comparisons made with Wilcoxon rank sum test;
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Compared to patients with other Psa strains, those with LES had a higher disease 
burden with higher hospital admission rates (median 6.8/pt/yr vs. 2.0, p<0.001), 
inpatient stays (median 60.2 days/pt/yr vs. 15.2, p<0.001), outpatient attendances 
(median 7.0/pt/yr vs. 4.7, p<0.01) and blood tests (median 7.1 vs. 5.0 p<0.001). There 
was a trend towards more TIVAD insertions, prevalence of depression and a need for 
radiological investigations in those with LES. 
 
There was also a significantly greater healthcare resource burden as evidenced by the 
requirement for more inpatient nursing time (median 391.0 vs 98.8 hours/pt/yr) and 
physiotherapy time (median 22.6 vs. 5.7 hours/pt/yr), higher inpatient stay costs 
(median £3549.4 vs 896.8/pt/yr), inpatient IV cost (£7123.0 vs 3088.9) (all p<0.001), 
outpatient attendance costs (£3502.2 vs 1706.2, p=0.003), and requirement for blood 
tests (9.5 vs 6.7, p<0.001) and radiological examinations (2.0 vs 1.3. p=0.05) 
 
Overall, the mean cost of caring for a CF patient with LES was more than that with 
other Psa strains (£14893.83 vs. £9074.02, p=0.001).  
However, there was no significant difference in the mean cost or duration of chronic 
treatments including inhaled mucolytic and antibiotic therapy, and oral immuno-
suppressives including macrolides and steroids. There were also no significant 
differences in home IV therapy or procedural costs (Port or PEG insertion) in patients 
with LES compared to other Psa strains. 
 
5.5 Discussion:   
There have been many studies focusing on direct healthcare costs associated with CF, 
typically from the perspective of a hospital or third party payer, all retrospective in 
design. Robson et al estimated the annual cost incurred by a UK adult unit (Robson et 
al 1992)
 
at £8241 per CF patient, with drugs (inpatient and outpatient) accounting for 
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57% of the total: costs for patients requiring regular intravenous antibiotics were 3 
times that of the average patient, with up to 21 times in the final stages of the disease.   
A US paediatric CF centre conducting a similar analysis estimated the average annual 
patient cost at $13300, with older and more severely ill patients consuming more 
resource ( Lieu et al 1999). However a German paediatric CF centre estimated the 
average yearly cost to be €23989 with outpatient drugs making up 47% of the total. 
(Baumann et al 2003)  A regression-based analysis revealed that both FEV1 and Psa 
colonisation correlated with cost, with patients colonised with Psa costing three times 
more than the remainder (Johnson et al 1999). This important finding highlights the 
contribution of Psa infection and its treatment to the overall economic burden of 
cystic fibrosis, yet despite this there have been no systematic studies looking at the 
effect of colonisation with epidemic Psa strains per se. Other studies looking at the 
economic aspects of cystic fibrosis have focussed on the cost effectiveness of 
interventions. 
 
Despite the advances in CF care over the last two decades, chronic respiratory 
infection with Psa still remains the main cause of morbidity and mortality, where 90% 
of the deaths are still due to end–stage respiratory failure. Over the last decade strains 
of Psa have emerged which are capable of cross-infecting other CF patients and other 
individuals. Some of these strains have been reported to possess characteristics, which 
make them more virulent, transmissible and adaptable to the CF lungs (Salunkhe et al 
2005). The most common epidemic strain in UK CF clinics is the Liverpool Epidemic 
Strain (LES) which was first reported at the paediatric CF centre in Liverpool, when 
Cheng et al demonstrated the presence of a ceftazidime resistant Psa strain possessing 
a single genotype in 85% of the clinic population. (Cheng et al 1996)
 
 LES is the most 
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prevalent transmissible Psa strain; it is widespread throughout UK CF clinics and has 
now spread to Canada (Aaron et al 2010). We have already shown that LES can cause 
an accelerated fall in FEV1, BMI and results in increased hospital stays. A number of 
other clonal strains have now been reported in UK and worldwide (Bradbury et al 
2008, Fluge et al 2001), many of which are associated with a poorer prognosis. 
However, chronic infection with such strains is not universally accepted as a poor 
prognostic factor (Tubbs et al 2001, Speert et al 2002, O’Carroll et al 2004). This may 
be because other factors (age, female sex, poor lung function and BMI, and CF related 
diabetes), which can also lead to higher morbidity and mortality in CF, have masked 
their effect. 
Nevertheless, since Psa is a well established poor prognostic indicator in CF, and 
poorer outcomes have been demonstrated following chronic infection with 
transmissible strains (Armstrong et al 2003, Jones et al 2001, Al-Aloul et al 2004), a 
higher healthcare resource burden and cost for centres looking after such patients is 
expected. Thus, for the first time we have demonstrated the disease burden and costs 
associated with chronic infection with the most important and prevalent epidemic Psa 
strain (LES). This prospective study compares the costs of caring for 40 LES-infected 
CF patients over 4 years attending a large adult CF centre in the north-west of 
England, with 40 other Psa-infected CF patients well matched for the important 
prognostic indicators of age sex, lung function, and CF-related diabetes mellitus.  
Using this substantial cohort, we have clearly demonstrated the increased healthcare 
disease burden and costs associated with LES infection: those with LES required 3 
times as many hospital admissions, 4 times more inpatient days and twice as many 
outpatient visits compared to those with unique Psa strains. This increased hospital 
resource use by patients with LES is also reflected in significantly higher inpatient IV 
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antibiotic use, blood tests, radiology examinations and the cumulative time spent by 
allied health professionals to care for these patients which add to the healthcare 
resource burden on the provider. Based on our data, on average the cost of caring for a 
patient with LES is at least 60% more than for a patient with a unique Psa strain. 
Although there were no significant differences in the use of chronic treatments or 
their duration between the groups, there was a suggestion that those with LES are 
commenced on these treatments earlier, perhaps reflecting an increase in the severity 
of their illness following LES acquisition. Although an increase in treatment burden 
following infection with transmissible strains has previously been demonstrated 
(Jones et al 2001), our study is much more detailed and focussed on the most virulent 
epidemic Psa, LES. We believe these differences are more reflective of the true 
disease burden faced by patients with LES and indicative of healthcare resource 
burden placed on the healthcare provider. Furthermore, a longer follow-up period and 
greater sample size confirms the previous results from our centre (Al-aloul et al 
2004).  
The reasons for this apparent increased cost of LES infection is unclear: although we 
have already shown that LES exhibits increased virulence factors such as the 
overproduction of pyocyanin, a dysregulation of quorum sensing mechanisms and the 
presence of genomic islands which could contribute to this (Winstanley et al 2009, 
Fothergill et al 2007) further study is required. We have also demonstrated that LES is 
associated with a poorer quality of life in CF patients, and this may increase their 
interaction and need for more healthcare resources, over and above their physical 
requirements (Ashish et al 2012). 
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There are limitations to our cost assessment: not all medications (e.g. inhalers, 
pancreatic supplements, and insulin) could be completely documented, and many 
medications have formulations that vary in cost and in the amount taken by each 
patient. Since such prescriptions are individually tailored to the patient, it is difficult 
to calculate an average value for these items for the purpose of cost estimation. The 
capture of outpatient costs is also difficult, where the use of extra medications (such 
as oral antibiotics) relies upon adequate documentation by the prescribing clinician, 
and as a result some may been missed. Also, it is impossible to determine exactly how 
much nursing and physiotherapy time each patient has required over time: some 
patients carry out their own physiotherapy regimens or use expectoration devices and 
may not require as much time as others. Conversely, severely unwell patients may 
require much more attention than the stipulated time outlined in the study. 
Furthermore, we have not incorporated the indirect costs associated with hospital 
admission or increased treatment (loss of income, travel costs, childcare costs etc), 
which may be attributable to poor health in an individual patient, estimated at up to 
60% in CF (Pauly, MV  1983). Moreover the costs associated with running parallel 
streams of outpatient clinics, and inpatient facilities have not been included. These are 
cost-intensive strategies introduced to minimise the spread of transmissible strains and 
are an important aspect of care for these patients. However, such missed costs would 
almost certainly be greater in the LES-infected patients, and their inclusion would 
therefore strengthen the differences between the two groups. It may also have been 
interesting to compare the current financial allocation to CF trusts based on banding 
and the estimated costs as per our study but that was outside the scope of our study. 
In conclusion, this study has shown that chronic infection with LES is an independent 
risk factor for a higher treatment burden in CF and therefore a greater cost to the 
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healthcare economy, than other strains of Psa. It also reinforces the need to prevent 
the spread of such transmissible Psa strains in CF clinics through stringent cross-
infection control measures. 
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Chapter 6 : Halting the Spread of Epidemic Pseudomonas aeruginosa in an Adult 
CF Centre: a prospective cohort study. 
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6.1 Abstract: 
 
Objectives:  To assess if cohort segregation policies are effective in preventing cross 
infection in CF (Cystic Fibrosis) clinics. 
Design: A prospective cohort study. 
Setting: A large adult Cystic Fibrosis Centre in Northwest England. 
Participants:  All CF patients cared for at the Liverpool Adult CF centre 2003-2009. 
Methods: Regular sputum sampling with genotyping of Psa isolates led to a policy 
of inpatient and outpatient segregation by microbiological group. 
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Main outcome measures:  Prevalence and cross-infection/super-infection rates of a 
transmissible Pseudomonas (Psa) strain i.e. the Liverpool Epidemic Strain (LES) in 
adult CF patients at the Liverpool Adult CF Centre from 2003-2009. 
Results:  There was a decline in the proportion of patients with LES (71% to 53%) 
and an increase in those with unique strains (23% to 31%) and without Psa infection 
(6% to 17%) from 2003 to 2009. There were two cases of LES super-infection and 
one case of new chronic Psa infection (with a unique strain). There were no cases of 
transmissible strain infection in patients previously un-infected by Psa.  
Conclusions: Our segregation policy has halted the spread of the commonest highly 
transmissible strain in the UK (LES) in our clinic, without endangering patients who 
were not previously infected with Psa. It confirms that if genotypic surveillance is 
used, it is unnecessary to segregate patients infected with unique strains from those 
without Psa infection.  
 
6.2 INTRODUCTION     
Although Cystic Fibrosis (CF) is the most common potentially lethal inherited disease 
in the Western World, due to improved management the life expectancy of CF 
patients has greatly improved in the last two decades and in the UK the median 
survival is 38 years (UK CF Registry 2008). However, the majority of patients still 
die from end stage lung disease, due to chronic bacterial infection with Pseudomonas 
aeruginosa (Psa) (Belkin et al 2006). Despite the success of aggressive therapy against 
acute infection/colonisation with this organism, most CF patients become chronically 
infected by early adulthood, and once established Psa is impossible to eradicate and 
can cause a rapid decline in clinical parameters, doubling their mortality. (Henry et al 
1992, Fredereiksen et al  1999, Kerem et al 1990)
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Initially it was believed that each individual harboured his or her own unique Psa 
strain which was incapable of cross infecting another individual (Speert et al 1987) 
with or without CF. However, in 1996 Cheng et al demonstrated the widespread 
presence of an antibiotic resistant Psa at the children’s CF centre in Liverpool, UK. 
Psa genotyping revealed the children to be infected with the same clone, and it was 
postulated that this particular variant may have the capability to spread to other 
individuals. Subsequently, we have shown that it can super-infect those with their 
own unique strains, (McCallum et al 2001)
 
in many cases replacing them, and can 
also spread to non-CF patients (McCallum et al 2002) and across species (Mohan et al 
2008). This variant, which has now been shown to be widespread throughout UK CF 
centres (Scott & Pitt 2004)
 
and has also been reported in Canada, (Aaron et al 2008)  
is labelled the Liverpool Epidemic Strain [LES]. Reports of other transmissible strains 
have now been made, not only in the UK (Jones et al 2001, Al-Aloul et al 2004, 
Edenborough et al 2004, Tubbs et al 2001, Denton et al 2002) but also elsewhere. 
(Armstrong et al 2003, Griffiths et al 2005, O'Carroll et al 2004, Bradbury et al 2008, 
Speert et al 2002, Dinesh et al 2003)  
The Liverpool Adult Centre receives patients from the paediatric centre, which 
reported the first outbreak of LES in 1996, and many of these children have grown up 
and transferred to the adult sector. A post-hoc analysis in 2000 (Panagea et al 2003) of 
sputum cultures from our CF patients identified LES in 79% of those chronically 
infected with Psa, demonstrating the widespread infection of patients inherited from 
the original reporting paediatric centre.  
To control this epidemic, in 2003 we implemented a strict cohort-based segregation 
policy for all our CF patients alongside our paediatric centre, monitored by regular 
Psa genotyping which includes markers for the most common known UK 
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transmissible Psa strains. All patients submit microbiological samples at every clinic 
visit/inpatient stay, and Psa isolates from those without known LES infection undergo 
genotyping every 3 months. Psa isolates from patients infected with LES undergo a 
genotypic check on a yearly basis. In 2009, 1098 genotype tests were carried out on 
Psa-infected patients. Using this system, we are aware of the Psa genotypes infecting 
our CF patients at all times.  
Based on this, those infected with LES are segregated together into a separate 
outpatient clinic and a 12-bedded purpose built inpatient facility, all with separate 
rooms. Patients infected with Burkholderia species or any known other transmissible 
Psa strains are isolated from all others, both as outpatients and inpatients. Other 
patients (including those infected without known transmissible strains of Psa and 
those without Psa infection) are not segregated from each other, since unique Psa 
strains by definition cannot spread between patients: this group are supervised in the 
same outpatient clinics and admitted to individual rooms on the same ward for 
inpatient treatment. Since patients known to be infected with transmissible strains 
attend outpatient clinics, radiology, lung function, and pathology and physiotherapy 
departments at different times and on different days to the remainder, we have 
ensured their complete segregation within the hospital environment.  
Patients chronically infected with MRSA are kept within-group, and managed 
according to the standard cross infection prevention protocols for this organism active 
in the hospital at the time. All our patients with CF are given strict instructions 
counselling them against mixing with other CF individuals, and those admitted to 
hospital agree a contract, which includes this.  
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We have continued this prospective surveillance for Psa strains among our patients 
from 2003 to date, and we now report the results of our segregation policy at our 
centre for 7 years, up to 2009. 
 
6.3 Microbiological Methods 
Lower airway microbiological samples are obtained for culture at every clinic visit 
and frequently (at least weekly) during inpatient treatment stays by a qualified 
physiotherapist. Wherever possible, sputum samples are preferred to cough swabs. 
The samples are sent in sealed sterile containers to the routine microbiology 
laboratory where they are processed in the standard fashion, within 24 hours, 
including subculture for Psa. Representative Psa isolates from each sample are stored 
for future potential Psa genotyping at -80
o
C. Using our surveillance protocol (outlined 
above) isolates are batched for genotypic analysis and the clinical database updated 
accordingly.  
Psa genotyping methods have evolved with time, and these have been incorporated 
into our laboratory protocol: 
 
 
2003-2005 
Psa genotyping was carried out using the RAPD (rapid amplification of 
polymorphic DNA) technique of sputum Psa isolates from all patients. 
(Mahentherelingam et al 1996) Ambiguous results were checked using PFGE 
(pulse field gel electrophoresis).  
2005-2008  
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The method was modified during PCR by using the primers PA-SS 
(Pseudomonas specific bands at 956 bp) and PS21 (LES specific bands at 
364bp) to identify LES-positive isolates. (Panagea et al 2003) LES-negative 
isolates by PS21/PA-SS underwent further typing using RAPD for comparison 
with other common epidemic strains (Manchester and Midlands1). 
2008-2009 
In March 2008, by combining the specific primers and modifying the product 
mix we identified LES, Manchester and Midlands1 strains from one test 
(Combined Multiplex PCR). (Fothergill et al 2008) Primer F9 added to the 
PCR mix increased the specificity of the test to identify LES.  
Chronic colonisation with Psa is defined as isolation of the organism in three or more 
successive samples taken at least 4 weeks apart over a 6 month period. Patients with 
Psa were classified as LES or other common known epidemic strain positive if any 
respiratory sample confirmed their presence on genotypic analysis, with the remainder 
defined as sporadic strains.  
Longitudinal follow up of CF patients  
Data on all existing patients and new patients joining the Liverpool adult CF centre 
from 2003 to 2009 were collected from hospital records and our departmental 
database.  
6.4 Results 
6.4.1 Clinic Demographics 
Over time, the adult clinic population has grown from 148 in 2003 to 244 in 2009.  
The proportion of patients chronically infected with Psa has diminished year on year, 
from 84% in 2003 to 74% in 2009 (see Figure 6.1). Of these, 71% were chronically 
infected with LES in 2003 and this proportion fell steadily to 53% in 2009 (p<0.001). 
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The proportion of patients transferring into the clinic from the paediatric sector also 
altered, with progressively fewer patients chronically infected by Psa, and of these, 
progressively fewer chronically infected by LES (see Table 6.1). During the study 
period, 56 patients have left the clinic (40 died [30 LES], 12 transferred elsewhere [6 
LES], and 4 lost to follow-up [all sporadic strains]. Patients who underwent lung 
transplantation remained with their original cohort since upper airway Psa infection 
with their original strain is presumed, whether or not the lower airway becomes re-
infected with Psa.  
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Fig 6.1: Prevalence of chronic Psa infection at the Liverpool CF clinic 2003-2009 
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T ab l e  6 . I :  In c i dence  and  p reva l en ce  o f  LES ,  Ot her  Psa  S t r a in s  
a nd  No  Psa  I n f ec t io n  a t  L i v erpo o l  Adu l t  Cys t i c  F ib ro s i s  Un i t  
2 0 03 -2 00 9  
 
  
 2003 2004 2005 2006 2007 2008 2009 
LES 
95  
(71%) 
105 
(70%) 
109 
(68%) 
116 
(63%) 
115 
(58%) 
115 
(56%) 
114 
(53%) 
Other Psa 
30  
(23%) 
31  
(21%) 
37  
(23%) 
45  
(25%) 
48  
(25%) 
56  
(27%) 
66  
(31%) 
No Psa 
8  
(6%) 
13  
(9%) 
15  
(9%) 
22  
(12%) 
32  
(17%) 
33  
(17%) 
36  
(17%) 
Super-
infection 
0 1 0 0 1 0 0 
Conversion 
(Non-Psa to 
Psa) 
0 0 0 0 0 0 1 
LES New 
Transfers 
11 11 10 10 7 6 3 
Other Psa 
New 
Transfers 
6 7 11 13 8 14 11 
Non-Psa New 
Transfers 
2 5 3 7 12 9 8 
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6.4.2 Super-Infection 
Over the 7-year period, 2 patients previously chronically infected with unique Psa 
strains have acquired LES (super-infection) (see Table 6.2). In both cases, these 
patients had undergone social contact with LES infected patients outside the hospital 
environment, despite appropriate counselling against this. There was no evidence of 
any nosocomial contact. 
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Table 6.2: Details of patients super-infected with LES attending the Liverpool 
Adult CF clinic 2003- 2009 
 
  
 
Date of 
joining 
service 
Sample 
type 
Date of 
conversion 
to LES 
Sample 
type 
Known social 
contacts with 
other LES pts 
Details 
1 Sept 1992 Sputum Sept 2004 Sputum Yes 
Socialised with 2 LES 
patients 
2 Aug 2005 
Cough 
swab 
July 2007 Sputum Yes 
Knew 2 LES patients 
from childhood, 
frequent socialisation 
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Pseudomonas Conversion 
There has only been one case of new chronic Psa infection in the uninfected cohort, 
despite attempted eradication. This occurred in 2009 and genotyping revealed a 
unique Psa strain. A further 6 patients developed acute infections with Psa (unique 
strains) and these were successfully eradicated using recommended protocols. There 
were no cases of patients without Psa becoming infected with either a known 
transmissible or an existing unique strain over the time period. 
6.4.3 Other Epidemic Strains 
Two patients are infected with the Midlands1 transmissible strain, one since the start 
of the screening process and another on presentation to our unit in 2005. Both these 
patients are managed separately from the rest of the clinic population and remain 
uninfected with any other epidemic Psa strain. 
 
6.5 Discussion:  
Traditional thinking suggested that CF patients with chronic lung infections harboured 
their own unique organisms, and could not transmit these to similar individuals. 
(Speert et al 1987) However, this was shown to be incorrect with the outbreak of the 
Burkholderia cepacia complex (Bcc) epidemic in CF patients attending Summer 
Camps in the US in the late 1980s. (Pegues et al  1994)
 
Not only could these 
organisms spread to Bcc naïve patients, (White et al 1995, Johansen et al 1998) but 
we also showed that different Bcc strains could spread to patients already infected to 
their detriment. (Ledson et al 1998) Subsequent stringent segregation of infected 
patients by the CF healthcare community halted this epidemic, (Muhdi et al 1996) and 
now few CF patients harbour these organisms. 
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However, at that time whether Pseudomonas aeruginosa might possess a similar 
ability was controversial since strains are indistinguishable by phenotypic methods 
alone. Although an increase in the incidence and prevalence of multi-resistant Psa was 
noted in a Danish CF centre in the 1980s, (Pedersen et al 1986)
 
and following 
phenotypic cohort segregation there was a fall in the annual incidence of new 
infections, other control measures (early eradication therapy for Psa infection and 
elective intravenous treatment for those with chronic infection) were also employed. 
These, coupled with a lack of genotypic identification of the resistant Psa isolates, 
meant the link between cohort segregation and improving clinical outcomes could not 
be made.  
Transmissible strains may be more antibiotic resistant and have been shown to confer 
a worse prognosis with increased treatment requirements, (Jones et al 2001, Bradbury 
et al 2008) inpatient hospital stays, worsening lung function and nutritional state, (Al-
Aloul et al 2004)
 
and will ultimately cause excess mortality (Armstrong et al 2002). 
Prevention of infection of CF patients with these strains is therefore paramount: since 
they do not survive long in the environment and nosocomial reservoirs have not been 
found, patient-to-patient contact is the likely source of their acquisition, such that 
patient segregation becomes the most important infection control measure.  
Unfortunately, CF care is complex and requires the coordinated efforts of a multi-
disciplinary team: whilst the grouping of patients together at dedicated centres is 
associated with improved outcomes, it also means they are potentially exposed to 
pathogens, in particular transmissible Psa strains (Mahadeva et al 1998).  
However, the degree of contact necessary between CF individuals to allow 
transmission of organisms is unknown: although we have shown that LES-infected 
patients produce an aerosol of viable infected droplets that can be detected for several 
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hours in the environment, and this clone also has an enhanced ability to survive on 
hard surfaces compared to other strains, (Panagea et al 2005) the amount of exposure 
necessary for host acute infection/colonisation with Psa in general remains unclear. 
Contact density must be an important factor in predicting cross infection: in adult 
patients, the limited contact possible within the environment of an outpatient visit is 
unlikely to be sufficient, and where cross-infection has been documented, this has 
followed an inpatient stay (McCallum et al 2002, Jones et al 2001). 
Nevertheless, complete avoidance of patient-to-patient contact is the gold standard to 
prevent the passage of organisms from one individual to another: under these 
circumstances, for inpatient care all CF patients would be accommodated in separate 
areas on different wards, and for outpatient care in separate clinics at separate times of 
the week.  
As regards outpatient care, it is impossible to review all patients entirely separately 
and some units use the approach whereby each patient remains in a single clinic room 
and is visited in turn by members of the CF MDT (Saiman et al 2003), thereby 
ensuring that patient-to-patient contact within the clinic should not occur. However, 
such a strategy is time consuming, limits the number of patients that can be seen in 
any one session and even if patients adhere strictly to appointment times, since they 
are invited to attend the hospital at the same time some mixing cannot be prevented. 
Furthermore, it is irrational to stringently segregate outpatients but not inpatients, 
where the risk of cross infection is much greater. 
Similarly as regards inpatient care, due to limited healthcare resources such 
segregation is difficult for most units, and many adopt the policy of admitting patients 
to the same facility, but in different rooms and with agreed rules of conduct whilst on 
the ward. However, children and young adults are gregarious and some mixing is 
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inevitable, especially at those social times in the evening and weekends which are 
difficult to police, and it has been shown that this strategy ultimately results in cross- 
infection (Jones et al 2010). 
Many adult CF clinics therefore use cohort segregation as the most practicable way of 
limiting cross-infection. However, Psa strains cannot be separated on phenotypic or 
antibiogram patterns (Davies et al 2003) such that policies which rely on these criteria 
will inevitably allow cross infection to occur. These include ones that segregate solely 
on multi-resistance or the separation of Psa positive from Psa negative patient groups. 
In the latter, those with sporadic strains cannot by definition cross-infect, and 
therefore their separation from those who are Psa negative is illogical, but they can in 
turn become super-infected by those in the Psa positive group with transmissible 
strains with the potential for consequent clinical deterioration (McCallum et al 2001). 
It therefore follows that, in order for any cohorting policy to be effective, the clinician 
needs to be aware of the strains of Psa in their CF clinic population in real time. This 
can only be achieved by Psa genotyping on a regular basis, allowing those with 
transmissible strains to be segregated from all other individuals.  
It is this policy we adopted in 2003 in our developing adult CF clinic, where 
increasing numbers of patients already infected with transmissible Psa (LES) were 
arriving from the local paediatric centre as they reached adulthood, and a cross-
sectional survey had shown a high prevalence of LES amongst our patients. Our 
results show that by using regular genotypic surveillance of Psa strains and 
segregating patient groups accordingly, we have prevented infection by nosocomial 
contact. The very few patients who have developed super-infection all did so through 
well documented social contact outside the hospital environment, despite advice to the 
contrary. It is of note that other units undertaking Psa genotypic analysis but without 
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effective patient segregation measures in place have noted a high cross infection rate 
with LES during this period. (Jones et al 2010) Furthermore, although we have not 
separated those without Psa infection from those infected with sporadic Psa strains, 
there has been only one new case of chronic Psa infection in this group (with a unique 
strain), underlining that it is unnecessary to separate these patient cohorts. A further 6 
cases of acute Psa infection with unique strains occurred, all of which were 
successfully eradicated – although previous studies (Frederickson et al 1999, Lee et al 
2004, McKay et al 2009) reported a higher incidence of such acute infections, these 
were carried out in a largely paediatric population where the prevalence of chronic 
Psa infection is much lower. 
There are financial consequences to adopting this genotypic surveillance protocol: 
each test costs approximately £20, and with the addition of technician time the yearly 
cost to our clinic is currently £22,000. This is likely to increase further, since although 
the relative numbers of patients infected with Psa strains is diminishing with time due 
to better cross-infection control and eradication therapy (particularly in paediatric 
practice), the absolute numbers continue to grow as more patients live longer. 
Nevertheless, we believe that not only is the cost of this testing outweighed by the 
clinical benefit, but there are strong economic arguments for its use. Firstly, 
segregating patient by other methods would necessitate an alteration in clinic and 
ward infrastructure, which would be costly and for some units impossible, and 
secondly cross infection with transmissible strains has been shown to confer an 
increased healthcare cost burden (Ashish et al 2010). Finally, the emerging medico-
legal consequences of allowing cross infection between CF patients within the 
hospital environment, which can be costly, are also avoided. 
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In conclusion, we recommend the use of genotypic surveillance of Psa strains, to 
allow rational segregation of CF patients. Using such a method, we have halted the 
epidemic in our clinic of LES, the most prevalent and important transmissible Psa 
strain within the CF community
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C hap t er  7 .  Gen era l  d i s cuss ion :  
 
7. 1 Conclusions 
In conclusion, this thesis has summarized some of the difficulties associated with 
chronic colonisation with the LES in the adult CF population. It has highlighted some 
of the problems faced by these patients, especially the quality of life and the 
psychosocial elements of chronic infection so often overlooked. 
Some of the microbiological aspects previously suspected to be associated with LES, 
such as enhanced antibiotic resistance, have been proven beyond any doubt in this 
thesis. We have shown the enhanced antibiotic resistance expressed by LES but also 
demonstrated that LES acquires antibiotic resistance much faster than the non-
epidemic strains. The reasons for such a characteristic of LES remain unexplained. 
Other characteristics attributed to LES, such as phenotypic diversity, presumed to be a 
reason for its success, have proven to be general characteristics of P. aeruginosa 
during chronic lung infections in CF. Our study of patients chronically infected with 
Non-LES strains has revealed an extensive phenotypically diverse population. We 
believe it is a characteristic of P. aeruginosa strains in general rather than a specific 
trait of LES or particular Non-LES strain. This has been confirmed by others, who 
have also reported extensive within-population phenotypic diversity for P. aeruginosa 
in CF (Darch et al 2015, Workentine et al 2013).  This raises the question as to why 
LES is so successful in colonising the CF lungs and causing morbidity and mortality. 
Research needs to address these questions at a molecular and basic microbiological 
level. A much more detailed understanding of LES is needed at a very basic level to 
further understand the reasons behind its dominance. There have been attempt to do 
this using genomics technologies.  In addition to the genome of LESB58, genome 
sequence data is now available for a number of other LES isolates from the UK and 
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Canada.  A recent study using genome sequencing suggests that chronically LES-
infected patients in the Liverpool CF Unit often harbour co-existing but divergent 
sub-lineages of the LES (Williams et al 2015).  The clinical significance of this is not 
yet understood, but it further emphasises the complexity of the infecting populations 
of bacteria in the CF lung.   
Another feature of the LES that could help to explain its success in competition with 
other strains of P. aeruginosa, is its carriage of multiple prophages (Winstanley et al 
2009).  A recent study has demonstrated that these LES prophages are very active in 
the production of free phages in the sputum of CF patients. (James et al 2015)   These 
represent considerable weapons against other competing strains and may contribute to 
the ability to cause superinfection.  
The host-bacterium interactions also need to be studied at a more detailed level.  
Cytokine responses (possibly exaggerated), long-term host adaptation to recurrent 
infective episodes and the role of viral agents in initiating these exacerbations need to 
be addressed. We also need to elucidate as to why some patients have rather well 
preserved lung function, better general health and are less susceptible to infective 
exacerbations, despite having the same genetic mutation and colonising organisms. In 
order to understand these issues, we not only have to study LES in detail but have to 
examine different hosts to understand these variable response and health effects. 
The thesis also sheds light on some of the larger issues faced by the institutions caring 
for CF patients, such as financial and infection control. It has been proven in the past 
that chronic infection with the LES in adult CF patients causes a rapid decline in lung 
function, BMI and overall health of an individual. This thesis also looks at the these 
effects further and investigates the burden LES places on the QoL of these individuals 
and wider resource implication at an institutional level caring for such patients. Our 
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institution looks after the largest number of patients chronically infected with this 
strain in the UK and possibly in the entire adult CF community. As a result of 
research within this thesis we have been able to show the health effects of chronic 
colonisation with this strain on the individual and at an institutional level. We have 
demonstrated that chronic colonisation with LES on an individual level causes not just 
physical decline in health but also results in a poor QoL on several measureable 
variables compared to individuals colonised with non-LES variant. This may further 
lead to poor compliance with medications, resulting in health decline that we witness 
with these individuals.  Although now we know that the LES can affect HRQoL 
outcomes, we need to address this issue more proactively and perhaps encourage 
patients to do this questionnaire on a yearly basis and offer the psychological support 
in individuals where a need is identified. In this way perhaps we could address the 
psychological burden of this disease. At the same time it would be interesting to study 
whether such an intervention may have any positive benefit to the lung function and 
to the overall outcomes of physical health. 
 
In previous studies we have identified that these strains are highly infectious and 
transmissible. This study looks at the preventative measures taken in our institution to 
control cross infection. We have demonstrated quite successfully that implementation 
of strict policies for elective and emergency hospital visits in a cohort of patients with 
various strains can be successfully implemented with minimal cross infection over a 
five-year period. The implementation of such policies requires a substantial monetary 
and personal investment. We need to be aware of the Psa genotype of all colonised 
individuals on a regular basis, especially those who harbour a non-LES strain. Cross 
infection issues such as those studied in CF, may also be relevant for other respiratory 
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infections, such as P. aeruginosa infections in non-CF bronchiectasis patients.  
Although one recent study, based on a single centre, suggested that cross infection 
might not be a common problem (De Soyza et al 2014), however further work is 
needed in this area. 
It remains a challenge to ensure there is no cross-infection, especially since the advent 
of a variety of ways of virtual social interaction among CF patients. As young adults 
they may trivialize the education we provide in order to fulfil their social 
intuitiveness. However our patient cohort remains well informed of the physical 
decline in heath that is seen with LES infection. Most CF patients have a social life, 
which may lead to cross infection. At an institutional level this causes severe 
problems of cross infection and to be able to care for hundreds of adult CF patients 
with various strains in itself remains a challenge.  
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7.2 Areas for future work: 
 
Despite an improved understanding of LES infections in patients with CF there are 
various aspects, which remain unclear. Some of the key questions that remain 
unanswered are: 
 
1. Why do only some patients with LES infection have severe ill effects whereas 
some individuals despite chronic colonisation have minimal co-morbidities? 
 
2. Why do female patients have a poorer outcome with LES infection? 
 
3. Strains such as the LES have genotypic and phenotypic features specific to it, so 
could we develop targeted therapies to eradicate /treat LES infection? 
 
4. What is the role of viral infections in acquisition of LES? 
 
5. Cross infection issues in Non-CF bronchiectasis 
 
More work needs to be carried out in this field, particularly in patients with chronic 
LES infection, to address these various questions which may help us look after these 
patients better, enabling them to lead a more fulfilling and normal life. 
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